The Longevity Digest 06/02 - 06/08
I'm cutting through the noise in longevity and anti-aging podcasts so you don't have to.
Welcome to The Longevity Digest.
I’ve curated specific shows that consistently deliver evidence-based insights you can actually use. Think less fluff, more substance. The kind of information that changes how you practice or how you live.
Got a podcast that’s been delivering gold? Send it my way. I’m always hunting for voices that push the field forward.
This Newsletter Is Sponsored By Casa de Sante.
Dr Onyx MD PhD’s Insights on this week’s episodes
The Body as an Operating System: Precision Medicine Takes Over from Population Medicine
The most disruptive signal running through this week’s episodes is simple but consequential: one-size-fits-all medicine is over. The Human Upgrade episode “Why Are Hackers Microdosing ‘Sex Drugs’ Now?” (Ep. 1425) made this viscerally clear — today’s leading longevity clinicians are no longer treating averages, they’re treating individuals. The operating framework is multi-omic: genomics, transcriptomics, proteomics, metabolomics, and exposomics layered together to reveal what’s actually driving a patient’s aging trajectory.
That shift demands a richer biomarker vocabulary. Beyond the standard cholesterol panel, the episodes this week consistently pointed to actionable signals that most labs still don’t run: ApoB, Lp(a), MMP-9, TGF-β1, and homocysteine for vascular and inflammatory risk; FSH and estradiol for women experiencing multi-system symptoms well before menopause; and even plasma tyrosine/phenylalanine ratios following a Mendelian randomization study (~270,000 participants) associating high circulating tyrosine in men with nearly one year shorter lifespan — a finding flagged on “Superhuman Contact Lenses, Motivation Supplement Stack...” (Ep. 1448). The strategic implication: your baseline lab panel is not your longevity panel.
Pharmacology is being individualized, too. The episodes collectively pushed back hard on blanket protocols. Metformin raises legitimate VO2 max and mitochondrial concerns; rapamycin data are still maturing (PEARL trial). In “Why Doctors Can’t Fix Women in 2026” (Ep. 1446), the case was made emphatically that women are routinely under-treated because dosing is anchored to lab “norms” rather than symptom resolution — particularly with bioidentical estradiol and progesterone, where systemic vaginal delivery may offer superior bioavailability over patches and oral routes. The actionable insight across all episodes: titrate to the patient, not to the population average.
This Newsletter Is Sponsored By Casa de Sante.
For anyone on GLP-1 medications like Ozempic or Wegovy, Low FODMAP nutrition is non-negotiable. These medications can slow digestion and trigger bloating or nausea, so choosing gut-friendly products helps you stay comfortable while protecting muscle and metabolism. Physician-formulated by Dr Onyx MD PhD Certified in Obesity Management, this Low FODMAP lineup supports nutrient absorption, muscle defense, and overall digestive balance:
Premium Protein Powder (Vegan Vanilla, Whey Vanilla, or Whey Chocolate) – helps preserve lean muscle during weight loss
FODMAP Digestive Enzymes – improves absorption and reduces GI side effects
Advanced Probiotic + Prebiotic Synbiotic Formula – supports a balanced gut microbiome
Essential Vitamin & Mineral Complex – replenishes nutrients often depleted during rapid weight loss
Gentle Colon Cleanse + Probiotic Support – aids regular elimination without irritation
All formulas are low FODMAP, non-GMO, and third-party tested—the ideal foundation for GLP-1 users focused on digestive comfort, metabolic health, and muscle preservation.
Because hormones and skin health are deeply connected, Dr Onyx MD PhD science-backed skincare supports barrier repair, hydration, and inflammation balance for healthy, resilient skin—especially during menopause or while using GLP-1 medications, when collagen loss and dryness can accelerate:
HydraLift Collagen Complex – firms and smooths for youthful elasticity
Antioxidant C+E Ferulic Radiance Serum – brightens and defends against oxidative stress
Needle-Free Wrinkle Smoother – softens fine lines without irritation
Ultra Retinol 10x + Bakuchiol Serum – boosts cell turnover with gentle plant retinol
Advanced Retinol Eye Repair – targets puffiness and under-eye wrinkles
Cellular Repair Growth Factor Peptides Serum – rejuvenates and supports skin repair
Advanced Neck Lift Firming Complex – improves tone and texture along the jawline and neck
Even Tone Brightening Cream – evens discoloration for radiant, balanced skin
Dr Onyx Adegbola MD PhD
Track Smarter. Eat Better. Thrive. Download the GLP1 Support App at https://casadesante.com/pages/app-glp-1-support-by-dr-onyx-md-phd
Your Cells Are the Pharmacy: Mitochondria, Epigenetics, and the New Biology of Aging
If precision medicine is the strategic framework, mitochondrial and epigenetic biology is the engine room. This week delivered a convergent, multi-source case that the primary target for longevity intervention is not a single drug — it’s the health of your cells’ energy and information systems.
Dr. Kara Fitzgerald’s work, spotlighted in “Eat These Foods + Spices for 8 Weeks To Get 3 Years Younger” (Ep. 1461), provides the most striking clinical proof point: an 8-week randomized controlled dietary intervention emphasizing methyl-donor foods (leafy greens, eggs, beets, liver) and polyphenol-dense herbs and spices produced a three-year reduction in biological age on the Horvath epigenetic clock in healthy middle-aged men. Crucially, re-analysis identified nutrients — not meditation or exercise — as the primary drivers. Think of it as reprogramming the software of your cells with information encoded in food. The protocol targets polycomb repressive complex 2 (PRC2), a regulatory system that may govern how cells “remember” their youthful gene expression patterns. Specific polyphenols — EGCG, urolithin A, rosemary, oregano — appear to partially mimic this reprogramming effect.
Urolithin A (Mitopure) received its own detailed treatment in “The Biblical Anti-Aging Fruit That Scientists Are Obsessed With” (Ep. 1470). This gut-derived postbiotic activates mitophagy — the cellular cleanup process that removes dysfunctional mitochondria before they poison the neighborhood — with human data showing increased naive CD8 T cells and NK cells, decreased inflammatory signaling, and upregulated mitochondrial gene expression in adults aged 50–70 after just four weeks at 1g/day. The caveat is critical for clinicians: only ~30–40% of people can convert pomegranate polyphenols into urolithin A via the gut microbiome, making pomegranate juice a poor substitute for a standardized supplement. Meanwhile, “The Strangest Thing I Do Every Morning” (Ep. 1458) with Brad Pitzele added a device-based angle — stacking Exercise with Oxygen Therapy (EWOT) immediately before red/near-infrared photobiomodulation (PBM) targets both sides of the cellular energy equation: oxygen delivery and mitochondrial oxygen demand, potentially breaking cycles of tissue-level pseudo-hypoxia that persist even when pulse oximetry looks normal.
The clinical synthesis: sleep, nutrition, movement, and targeted supplementation are not lifestyle adjuncts — they are the primary drugs. The Health Longevity Secrets episode “Sleep Isn’t For Muscle Repair” reframed sleep as a neuroendocrine therapy: just four nights of four-hour sleep can induce prediabetic insulin resistance in healthy adults, crash testosterone by 10–15%, and blunt the night’s critical growth hormone pulse. Sleep is not recovery. Sleep is the intervention.
The Social, Environmental, and Behavioral Wildcard: The Exposome Enters the Clinic
The third convergent theme this week is perhaps the least discussed but the highest leverage: the environment your patient lives in — physical, social, and behavioral — is actively aging them, often faster than their genes.
Start with the physical environment. The Human Upgrade’s “Your AC Is Making You Dumber” (Ep. 1444) made the provocative but mechanistically coherent case that water-damaged buildings and HVAC systems are underrecognized drivers of multisystem illness — fatigue, brain fog, endocrine disruption, sleep disruption — via fat-soluble mycotoxins that act as mitochondrial poisons. Approximately 28% of people carry HLA-DR4 variants that impair mycotoxin clearance, explaining why one family member can be severely affected while others appear fine. This is no longer a fringe concern: it’s exposomics entering the clinic. Similarly, “Semen Switch, Chewing Gum, Creatine Cheat...” (Ep. 1467) revealed that standard chewing gum — including products marketed as “natural” — shed hundreds to 3,000 microplastic fragments per stick into saliva, while a companion episode highlighted that sulforaphane may accelerate elimination of intracellular microplastics via lysosomal exocytosis. The practical message is clear: the toxic burden of modern life is measurable, modifiable, and clinically relevant.
Then there’s the social environment. Two Huberman Lab episodes this week built a coherent, biologically grounded case that social isolation is not merely unpleasant — it is a druggable disease state. Dr. David Anderson (“Essentials: The Biology of Aggression, Mating & Arousal”, Apr. 9) showed that social isolation robustly upregulates tachykinin 2 signaling across species, driving aggression, fear, and anxiety — phenotypes reversible with an NK3 receptor antagonist (osanetant) in preclinical models. Meanwhile, Dr. Dacher Keltner (“Cultivating Awe & Emotional Connection in Daily Life”, Apr. 6) offered the antidote: deliberate awe — 20–30 minute “awe walks” once weekly for 8 weeks — measurably increases vagal tone, reduces inflammatory markers, and lowers physical pain in older adults. Awe is not a wellness trend. It is a low-cost, high-yield anti-inflammatory intervention with a trackable mechanism. Dr. Nick Epley’s appearance (“How to Overcome Social Anxiety”, May 18) added the behavioral layer: graded, real-world social exposure — not simulation — is the evidence-based corrective for social anxiety, and even brief daily interactions (a greeting, a compliment, a short phone call) reliably lift mood and reduce the biological burden of isolation.
The strategic takeaway for clinicians is integrative: assess the exposome — the home environment, social connectivity, circadian regularity, and toxic burden — with the same rigor applied to biomarkers. The Finnish cohort data cited in Ep. 1467 found that objectively irregular bedtimes alone were associated with roughly double the risk of major cardiovascular events over a decade. Circadian regularity, social connection, and a low-toxin environment are not lifestyle recommendations. They are primary prevention strategies with measurable biological targets.
This weeks episodes:
1. The Human Upgrade: Biohacking for Longevity & Performance
Why Are Hackers Microdosing “Sex Drugs” Now? : 1425
Published: 2026-03-03
URL: Listen Here
Summary
This episode advocates for precision medicine that integrates multi-omic data, autonomic modulation, and targeted therapeutics to optimize longevity. It highlights vagal nerve stimulation’s ability to downregulate the NLRP3 inflammasome, the need to individualize drugs and peptides, and the centrality of vascular tone/perfusion and mitochondrial function to healthy aging. Some claims are anecdotal and product-related; specific study details were not always provided in the discussion.
Key Takeaways
Precision medicine should move beyond one-size-fits-all epidemiology to N-of-1 care using multi-omics (genomics → transcriptomics → proteomics → metabolomics/exposome) to match the right intervention to the right person at the right time.
Vagal nerve stimulation engages the cholinergic anti-inflammatory pathway (α7nAChR/JAK–STAT/NF-κB) and can downregulate the NLRP3 inflammasome, a central driver of systemic inflammation and fibrosis; simple adjuncts like EGCG may also modulate NLRP3 activity.
Longevity pharmacology must be individualized: metformin is not universally beneficial (mitochondrial blunting/VO2 max concerns), rapamycin safety data are emerging (PEARL trial) but endpoints matter, and low-dose, pathway-targeted use of drugs and peptides (e.g., BPC-157, KPV, CJC-1295 with ipamorelin, PT-141) can have bioregulatory effects when used judiciously.
Vascular tone and perfusion are foundational to brain and sexual health; strategies include nitric oxide support, selective PDE5 inhibitor use (e.g., low-dose tadalafil in appropriate patients), and device-based approaches like acoustic shockwave therapy, which may promote neovascularization and lower MMP-9.
Actionable biomarkers beyond routine labs that inform aging biology include homocysteine, ApoB, Lp(a), TGF-β1, MMP-9, and C4a; pairing these with mitochondrial/energy-oriented interventions (IHHT, photobiomodulation, PEMF, HBOT) and exposome assessment can improve outcomes while AI can help sequence interventions efficiently.
Clinical Insight
Targeting autonomic balance and inflammatory set-points—specifically via vagal nerve stimulation to suppress NLRP3—combined with multi-omic profiling provides a practical, high-leverage way to personalize longevity care beyond traditional risk-factor management.
Actionable Takeaway
In patients with chronic inflammation or dysautonomia, add MMP-9 and homocysteine (along with ApoB, Lp(a), TGF-β1, and C4a when feasible) to baseline labs; if elevated, trial a noninvasive vagal nerve stimulation protocol to engage the cholinergic anti-inflammatory pathway and reassess biomarkers after 6–8 weeks.
2. The Human Upgrade: Biohacking for Longevity & Performance
Why Are Hackers Microdosing “Sex Drugs” Now? : 1425
Published: 2026-03-03
URL: Listen Here
Summary
This episode explores how precision medicine leverages multi-omics, exposome assessment, and autonomic modulation to individualize care, with practical discussion of peptides, low-dose pharmaceuticals (e.g., tadalafil), and advanced biomarkers beyond standard panels. The conversation emphasizes sequencing interventions for mitochondrial and vascular health, measuring transcriptomic responses to confirm epigenetic effects, and safeguarding data as personalized platforms mature.
Key Takeaways
Precision medicine requires an N-of-1, multi-omic approach (genomics, transcriptomics, proteomics, epigenetics, metabolomics, exposomics) to match the right intervention to the right person at the right time.
Autonomic modulation, particularly vagal nerve stimulation, can downregulate inflammatory pathways (e.g., NLRP3 inflammasome via the cholinergic anti-inflammatory pathway) and may improve longevity-relevant markers; EGCG was cited as a practical adjunct.
Microdosing or low-dose use of select pharmaceuticals (e.g., tadalafil for vascular tone) and emerging peptide therapeutics (e.g., BPC-157, KPV, CJC-1295 with ipamorelin/semorelin, PT-141) can be useful for targeted outcomes but should be sequenced thoughtfully; metformin and rapamycin are not universal longevity solutions.
Beyond routine labs, clinicians should consider biomarkers that reflect inflammation and vascular health such as homocysteine, MMP-9, TGF-β1, C4a, nitric oxide-related function, and even cell membrane lipidomics; low cerebral perfusion is common and clinically meaningful.
Biohacking technologies (e.g., intermittent hypoxic–hyperoxic training, photobiomodulation, PEMF, HBOT, acoustic shockwave) can be potent when applied in the right order and tracked with objective data; data privacy and ownership matter as multi-omic and exposome assessments scale.
Clinical Insight
Shifting from population averages to multi-omic, N-of-1 care—while actively modulating the autonomic nervous system—allows physicians to directly influence and verify changes in key inflammatory and vascular pathways (e.g., NLRP3, nitric oxide biology), improving precision and efficiency of interventions.
Actionable Takeaway
For patients with chronic inflammation, dysautonomia, or low perfusion, implement daily noninvasive vagal nerve stimulation (or paced-breathing/HRV training) for 10–20 minutes and track CRP/IL-6 and symptom changes; consider adding a well-tolerated green tea extract providing 200–400 mg EGCG/day as an NLRP3-modulating adjunct, checking for drug–supplement interactions.
3. The Human Upgrade: Biohacking for Longevity & Performance
Your AC Is Making You Dumber : 1444
Published: 2026-04-03
URL: Listen Here
Summary
This episode argues that air-conditioning and water‑damaged indoor environments expose occupants to mycotoxins that impair mitochondrial function, cognition, hormones, metabolism, and sleep, with variable susceptibility driven partly by HLA‑DR genetics. The hosts outline a cost‑conscious, stepwise approach to ‘detoxing’ homes and vehicles—fix moisture/HVAC, oxidize/degrade mycotoxins and VOCs, reseed with environmental probiotics, and protect high‑risk surfaces—alongside humidity and dust control. Limitations: many claims are experiential or product‑specific and not independently detailed in the episode; clinicians should interpret promotional elements cautiously and corroborate with evidence-based resources.
Key Takeaways
Toxic mold and their mycotoxins (e.g., ochratoxin A, zearalenone) are fat‑soluble mitochondrial poisons that can drive multisystem illness—neurocognitive deficits, sleep disturbance with vivid nightmares, mood/behavior changes, endocrine disruption (thyroid, estrogen dominance), weight gain, easy bruising, recurrent infections, and chemical sensitivity.
Susceptibility varies widely; genetics (e.g., HLA‑DR4 variants) and exposure history modulate risk, so one family member may be severely affected while others appear well. Brain SPECT data (Amen Clinics) suggest mold exposure can reduce prefrontal activity and cognition but may be reversible after remediation.
Built environments—especially HVAC systems, ductwork, dust, moisture-prone areas, and vehicles—are common and underrecognized exposure sources; ingestion via mold‑prone foods (coffee, grains, peanuts) also contributes.
Effective management pairs medical care with environmental strategies: identify and fix moisture sources, control indoor humidity (~40–50%), address HVAC and duct contamination, reduce dust, and consider staged decontamination (oxidizing fog/gas to degrade mycotoxins and VOCs, reseeding with environmental probiotics, and protective coatings on high‑risk surfaces).
Porous belongings can carry residual mycotoxins between homes; moving without decontaminating contents often perpetuates illness. Vehicles (cars/RVs) can be significant sources due to mold and VOCs; targeted ‘detox’ is different from standard detailing.
Clinical Insight
In patients with persistent, unexplained multisystem symptoms (fatigue/brain fog, sleep disruption, mood/behavior changes, weight dysregulation, chemical sensitivity), assessing and treating the home/vehicle environment—especially moisture control and HVAC/dust contamination—can be decisive for recovery from mycotoxin-related illness.
Actionable Takeaway
Screen for water‑damaged building exposure in symptomatic patients and recommend a basic home assessment: measure/maintain indoor humidity at 40–50%, use HEPA air filtration and HEPA vacuuming to reduce dust, inspect/clean HVAC and ducts, and initiate validated environmental testing (e.g., dust-based mycotoxin or ERMI/HERTSMI‑2) before escalating medications.
4. The Human Upgrade: Biohacking for Longevity & Performance
Your AC Is Making You Dumber : 1444
Published: 2026-04-03
URL: Listen Here
Summary
Dave Asprey and the SuperStratum team discuss how indoor mold and residual mycotoxins can impair mitochondrial function and contribute to wide-ranging symptoms, with variable patient susceptibility. They outline practical, staged approaches for homes and vehicles—addressing moisture control, HVAC/duct hygiene, dust removal, and targeted decontamination of mycotoxins/VOCs—to complement or follow traditional remediation.
Key Takeaways
The episode centers on indoor mold and mycotoxins as underrecognized drivers of diverse symptoms (fatigue, brain fog, sleep disturbance, mood changes, endocrine disruption, weight gain) via mitochondrial dysfunction and immune dysregulation.
Susceptibility varies widely; about 28% of people may carry HLA-DR4 variants associated with heightened inflammatory responses and reduced ability to clear fat-soluble mycotoxins, which helps explain why household members can be affected differently.
Common exposure sources include water-damaged buildings, high indoor humidity, HVAC/ductwork, dust accumulation, and vehicles; ochratoxin A (OTA) and zearalenone are highlighted as clinically relevant mycotoxins with thyroid and estrogenic effects, respectively.
Post-remediation illness can persist due to residual mycotoxins and VOCs on surfaces and in contents; the discussion emphasizes whole-home strategies: fix moisture sources, maintain 40–50% indoor RH, clean/coat HVAC and ducts, HEPA vacuum dust, and consider targeted decontamination approaches.
The guests discuss a staged approach they use (fogging/‘bombing’ to oxidize mycotoxins/VOCs, followed by environmental probiotics and durable anti-microbial coatings) as a lower-cost adjunct to traditional remediation, and note cars can require similar detox protocols.
Clinical Insight
In patients with otherwise unexplained neurocognitive, endocrine, sleep, or cardiometabolic complaints—especially with a history of dampness or water damage—environmental mycotoxin exposure is a plausible, often overlooked contributor; assessing susceptibility, the built environment (not just visible mold), and residual mycotoxins after remediation can materially influence outcomes.
Actionable Takeaway
Incorporate a brief environmental history and screening into visits for chronic, multisystem complaints: ask about water damage/musty odors, humidity levels, HVAC maintenance, visible condensation, dust burden, and car exposures; advise maintaining indoor RH ~40–50%, fixing moisture intrusions, HEPA vacuuming dust, servicing/cleaning HVAC and ducts, and consider referral to qualified mold assessment/remediation when indicated.
5. Huberman Lab
Cultivating Awe & Emotional Connection in Daily Life | Dr. Dacher Keltner
Published: 2026-04-06
URL: Listen Here
Summary
This episode details the science of awe—how shifting from narrow to vast perception, engaging with nature and music, and synchronizing in groups reliably evokes awe with tangible benefits across inflammation, vagal tone, pain, and well-being. Practical protocols (e.g., awe walks) offer clinicians scalable tools to augment care, while insights on social bonding (embarrassment/teasing) and carefully supervised psychedelic-assisted therapy highlight additional pathways to strengthen connection and resilience. Note: Some findings (e.g., long COVID improvements from brief daily awe) are preliminary and require further peer-reviewed validation.
Key Takeaways
Awe is a measurable, health-relevant state linked to increased vagal tone (HRV), reduced inflammation, lower physical pain, and reported improvement in long COVID symptoms from brief daily awe practices.
Shifting perceptual “aperture” from small to vast (for example, moving from focusing on a leaf to the canopy to the sky/horizon) reliably evokes awe and can recalibrate arousal, time perception, and self-focus toward equanimity.
An 8-week, once-weekly 20–30 minute “awe walk” intervention in older adults increased awe, kindness, and vast attention in daily life and reduced bodily pain, with longer-term follow-up suggesting brain health benefits.
Group synchrony (music, sport, dance, chanting, shared rituals) rapidly fosters bonding and collective identity, consistent with the concept of collective effervescence; embarrassment and prosocial teasing within groups signal commitment to norms and strengthen cohesion.
Psychedelics (classic serotonergic agents) can induce profound awe and may aid treatment-resistant conditions (e.g., end-of-life anxiety, depression, PTSD) when used in structured, safe, culturally respectful settings; microdosing lacks strong clinical evidence.
Clinical Insight
Awe can be deliberately elicited (nature, music, horizons, group synchrony) and functions as a low-cost, low-risk adjunct that measurably improves autonomic balance (vagal tone), reduces inflammatory load and pain, and supports mental health—making it a viable element to integrate into preventive care and rehabilitation plans.
Actionable Takeaway
Prescribe a weekly 20–30 minute awe walk for 8 weeks: ask patients to slow their pace and breath (prolonged exhalations), and to move attention from small to vast (e.g., a leaf → tree → treeline → clouds/horizon). Encourage one brief daily “micro-awe” (≈60 seconds via nature, music, or vistas). Track simple outcomes (pain ratings, mood/sleep, HRV if available) and consider adding music- or nature-based sessions for reinforcement.
6. Huberman Lab
Essentials: The Biology of Aggression, Mating & Arousal | Dr. David Anderson
Published: 2026-04-09
URL: Listen Here
Summary
This episode reviews the neurobiology of internal states governing aggression, mating, and arousal, emphasizing hypothalamic circuit logic, hormone signaling (notably estrogen pathways), and brain–body interactions. It highlights how social isolation engages conserved tachykinin mechanisms that amplify aggression and anxiety, suggesting concrete translational avenues (e.g., NK3 antagonists) while underscoring the clinical need to assess and address isolation.
Key Takeaways
Emotions are best understood as internal brain states (like arousal or motivation) that reshape input–output transformations of neural circuits; unlike reflexes, they often persist beyond the trigger and generalize across contexts.
Aggression is a heterogeneous set of behaviors supported by distinct but adjacent hypothalamic circuits (VMHvl): fear-related neurons can hierarchically suppress offensive aggression, and VMH integrates multisensory inputs while broadcasting low-dimensional ‘attack pressure’ signals widely.
Sex hormones do not map simply onto behavior: estrogen receptor–expressing neurons in male VMH are necessary for aggression, many testosterone effects are mediated via aromatization to estrogen, and in females, discrete VMH ER+ neuron subsets differentially control mating versus fighting.
Mating and aggression circuits exhibit reciprocal control: activating medial preoptic area (MPOA) ‘mating’ neurons can abruptly switch a male from fighting to courtship, whereas VMHvl ‘aggression’ neurons bias toward attack; PAG acts as a downstream ‘switchboard’ coordinating pain modulation and innate action patterns.
Social isolation robustly upregulates tachykinin signaling (e.g., tachykinin 2) across species, increasing aggression, fear, and anxiety; in mice, an NK3 receptor antagonist (osanotont) reverses isolation-induced phenotypes without sedation, highlighting a translational target for isolation-related psychopathology.
Clinical Insight
Social isolation is a potent, biologically mediated driver of negative affect and aggression—partly via tachykinin 2 signaling—with preclinical evidence that NK3 receptor antagonism can normalize isolation-induced aggression, fear, and anxiety without sedation; clinicians should treat isolation as a modifiable risk factor rather than a benign social state.
Actionable Takeaway
Routinely screen patients for social isolation (e.g., recent bereavement, living alone, limited social contact) and implement mitigation strategies—structured social engagement, therapy referrals, family/caregiver involvement, and follow-up touchpoints—especially in individuals showing increased irritability, anxiety, or aggression.
7. Huberman Lab
Essentials: The Biology of Aggression, Mating & Arousal | Dr. David Anderson
Published: 2026-04-09
URL: Listen Here
Summary
This episode synthesizes neural circuit, hormonal, and neuropeptide mechanisms underlying aggression, mating, arousal, and pain modulation. Key themes include hypothalamic control of offensive aggression and its suppression by fear, estrogenic regulation of male aggression, sex-specific VMH circuits for mating vs fighting, and tachykinin-driven effects of social isolation that are reversible with NK3R antagonism—findings with clear translational relevance for stress-related behavioral health.
Key Takeaways
Emotions are best understood as internal brain states (like arousal, motivation, sleep) that transform how inputs map to outputs; compared to reflexes, emotion states show persistence and generalization beyond the initial trigger.
Aggression is a behavior that can arise from different internal states (e.g., anger, fear, hunger); in mice, ventromedial hypothalamus (VMHvl) circuits drive offensive, positively valenced aggression, while adjacent hypothalamic fear circuits can hierarchically suppress fighting.
Hormonal control of aggression in males depends critically on estrogen receptor–expressing VMH neurons and aromatization of testosterone to estrogen; estrogen implants can restore aggression in castrated male mice.
Sex-specific neural architecture shapes behavior: in females, distinct estrogen receptor–positive VMH subsets separately control mating and fighting, and medial preoptic area (MPOA) ‘mating’ neurons can acutely suppress ongoing aggression (antagonistic VMH–MPOA interactions).
Social isolation upregulates tachykinin signaling (Tac2/neurokinin B) across the brain to increase aggression, fear, and anxiety; an NK3 receptor antagonist (osanetant) reverses these effects in mice. The periaqueductal gray (PAG) acts as a hub for innate behaviors and supports endogenous, state-dependent analgesia (e.g., during fear/defense).
Clinical Insight
Chronic social isolation induces a Tac2/NK3R-mediated, druggable brain state that heightens aggression, fear, and anxiety—highlighting both the clinical importance of assessing isolation/bereavement and the translational potential of NK3 receptor antagonism for stress-related behavioral dysregulation.
Actionable Takeaway
Routinely screen patients experiencing prolonged social isolation or bereavement for irritability, aggression, and anxiety, and implement structured social reconnection strategies (e.g., group therapy, regular follow-ups, community engagement) to mitigate these biologically primed risk states.
8. The Human Upgrade: Biohacking for Longevity & Performance
Why Doctors Can’t Fix Women in 2026 : 1446
Published: 2026-04-09
URL: Listen Here
Summary
This episode argues that modern care under-treats women’s hormones and that personalized, bioidentical HRT—especially estradiol and progesterone delivered vaginally at systemic doses—can be a cornerstone for restoring libido, cognition, mood, sleep, gut/gallbladder function, and overall vitality. The guests emphasize treating to clinical response (not just numbers), considering genetics and neurotransmitters, and leveraging nutrition (adequate protein, cautious fiber, iodine) while using testosterone judiciously. Note: Many claims were experiential and not directly cited; sponsor content and controversial viewpoints are included.
Key Takeaways
Personalized, bioidentical hormone replacement (estradiol, progesterone, ± testosterone) is presented as foundational for many symptomatic women—even premenopausally—with dosing guided by symptoms and function rather than fixed lab ‘norms’ or low-dose patches/pills.
Systemic vaginal delivery of estradiol and progesterone is advocated as higher bioavailability than oral/topical/patch routes, aiming to suppress elevated FSH and improve cognition, sleep, mood, gut/gallbladder function, and sexual function; oral progesterone’s sedating effects may arise from liver-derived metabolites.
Testosterone can benefit women’s libido and cognition but excess transdermal/injected T may increase DHT/aromatization or disrupt the vaginal microbiome; many women may normalize T by optimizing progesterone, with optional low-dose topical T for event-based arousal.
Diet and environment meaningfully influence hormones and neurotransmitters: prioritize adequate protein (supporting dopamine/COMT), avoid excessive insoluble fiber and certain phytoestrogens, consider iodine repletion for breast/uterine health, and be mindful of high-oxalate foods (e.g., matcha/spinach) implicated in kidney stones and tissue symptoms.
Evaluate and treat holistically: use FSH and symptom clusters to detect early dysfunction, recognize genetic/epigenetic differences (e.g., COMT) in hormone clearance, consider neurotransmitter support (dopamine/norepinephrine/serotonin), and avoid focusing on thyroid alone when sex-hormone deficits drive multi-system complaints.
Clinical Insight
For women with multi-system symptoms (mood, sleep, gut, libido, cognitive), adequately dosed, bioidentical estradiol plus progesterone—preferably via systemic vaginal delivery—and personalized titration to clinical response can restore function across brain, immune, gut, and sexual domains; labs (including FSH) inform but should not replace symptom-guided care.
Actionable Takeaway
In an appropriate symptomatic woman (even <45), obtain FSH, estradiol, progesterone, total/free testosterone, SHBG, DHEA-S, and thyroid panel; if findings and history suggest ovarian under-function, initiate a trial of bioidentical estradiol + progesterone via systemic vaginal delivery and titrate every 6–8 weeks to symptom relief while reinforcing adequate protein intake and avoiding excessive insoluble fiber.
9. The Human Upgrade: Biohacking for Longevity & Performance
Superhuman Contact Lenses, Motivation Supplement Stack, Cat Scratches Cause Brain Fog, Amino Acid Shortening Lifespan, and more... : 1448
Published: 2026-04-10
URL: Listen Here
Summary
This episode highlights overlooked inputs—stealth infections, amino acid balance, sensory light processing, micronutrient status, and olfactory cues—that materially affect cognition, motivation, and autonomic tone. It offers practical steps clinicians can use now: targeted PCR testing for Bartonella, judicious lab monitoring around tyrosine, nutrient stacking to bolster motivation, and low-cost sensory strategies to reduce cognitive and stress load.
Key Takeaways
Cat scratches/bites can transmit Bartonella, a stealth infection linked to chronic brain fog, mood instability, and fatigue; standard serology often misses it—PCR testing is preferred and may require referral to a Lyme-literate clinician.
A Mendelian randomization analysis (~270,000 participants) associates higher circulating tyrosine with nearly one year shorter lifespan in men (not women), potentially via myeloperoxidase-driven formation of inflammatory meta-tyrosine; consider measuring plasma tyrosine and phenylalanine and avoiding unnecessary tyrosine supplementation, especially in men.
Tinted contact lenses (Altius) reportedly reduce chromatic aberration by 53% and improve contrast by 20–30%, potentially lowering visual processing load and enhancing performance; spectrum-filtering eyewear (e.g., TrueDark) and screen apps (Flux/Iris) are adjuncts.
A randomized, placebo-controlled crossover trial from the University of the Philippines found a 4-week stack (taurine 2 g, methylfolate 800 mcg, P5P 50 mg, methylcobalamin 1 mg) increased effort-based motivation and reduced attention lapses, plausibly via astrocytic glutathione support of prefrontal function.
A Monell Chemical Senses Center analysis indicates a 30-second deep nasal inhalation of floral scents can lower heart rate by 5–10 bpm and shift autonomic tone toward parasympathetic; lavender has the strongest RCT support, but pleasant florals broadly appear effective.
Clinical Insight
In patients with persistent neurocognitive or mood symptoms and a history of cat scratches/bites, Bartonella infection is likely underrecognized; order a Bartonella PCR (not just serology) and consider referral to a tick-borne disease–literate clinician, as antibody tests can miss intracellular, tissue-resident infections.
Actionable Takeaway
For patients (especially men) using tyrosine-containing supplements or very high-protein diets, obtain a fasting plasma tyrosine and phenylalanine panel (Quest/LabCorp) and review inflammatory markers; avoid or reduce tyrosine supplementation if levels are high or the tyrosine:phenylalanine ratio approaches/exceeds 10:1.
10. The Human Upgrade: Biohacking for Longevity & Performance
CDC Director Jim O’Neill on Fixing America’s Broken Food Policy : 1449
Published: 2026-04-14
URL: Listen Here
Summary
This episode features Jim O’Neill outlining an HHS/CDC push to overhaul U.S. food guidance and aging research while refocusing CDC on infectious diseases. Highlights include whole‑food, higher‑protein dietary guidance with forthcoming RCTs on saturated fat, large ARPA‑H investments in causal aging biomarkers and organ bioprinting, and greater openness to AI, wearables, non‑pharma therapies, and GLP‑1s. Several claims are policy announcements or opinions presented without primary citations.
Key Takeaways
The guest describes newly released federal dietary guidelines that emphasize whole and minimally processed foods, higher protein intake (1.2–1.6 g/kg/day), and allow meat and full‑fat dairy, while de-emphasizing refined grains and ultra‑processed foods; randomized controlled trials on saturated fats are being initiated.
HHS is prioritizing rigorous replication and aging science, including a reported $144M ARPA‑H initiative to identify causal biomarkers of aging and an organ bioprinting program that has printed a pediatric heart/vasculature (not yet implanted).
CDC is being refocused on infectious diseases, with examples cited of assisting to contain Ebola (DRC) and Marburg (Ethiopia), alongside a stated goal of rebuilding public trust through transparency.
There is openness to evaluating non‑pharmaceutical interventions (e.g., ozone therapy) with the same standards as drugs, and to integrating AI and wearables into care and surveillance—paired with strong patient consent and privacy protections.
Clinical and policy notes include support for GLP‑1s in obesity treatment, an ongoing review of upper vitamin D limits, and improvements to school meals aligned with the updated guidelines.
Clinical Insight
A shift toward whole‑food, higher‑protein nutrition with a more individualized view of dietary fats suggests clinicians should reassess grain‑centric, low‑fat counseling and focus on reducing ultra‑processed carbohydrates while tailoring fat and protein recommendations to each patient’s metabolic risk and goals.
Actionable Takeaway
For adult patients—especially those with metabolic syndrome risk or sarcopenia—calculate and document an individualized daily protein target of 1.2–1.6 g/kg from whole‑food sources, pair this with counseling to minimize ultra‑processed/refined carbohydrates, and reassess lipid/metabolic labs to tailor fat recommendations.
11. Huberman Lab
How Women Can Improve Their Fertility & Hormone Health | Dr. Natalie Crawford
Published: 2026-04-13
URL: Listen Here
Summary
Dr. Crawford details a proactive, science‑based roadmap for improving female fertility and hormone health: use AMH and ovulation tracking to detect issues early, leverage high‑impact lifestyle changes and targeted supplements during the “trimester zero,” and apply appropriate medical tools without waiting for failure. She emphasizes avoiding cannabis and nicotine, practical contraception off‑ramp timing, and clarifies that egg freezing/IVF do not reduce ovarian reserve, while highlighting select promising but still investigational therapies. Note: Summary reflects the provided transcript and may omit topics discussed outside these excerpts.
Key Takeaways
Proactive fertility assessment matters: Anti-Müllerian Hormone (AMH) testing estimates ovarian reserve (not egg quality) and can guide life and treatment planning; it’s inexpensive (~$79) and useful even before trying to conceive.
Track ovulation, not just periods: A luteal phase <11 days is an early red flag for ovulatory dysfunction; avoid NSAIDs except during menses because they can block follicle rupture and ovulation.
Lifestyle and exposures strongly influence fertility and hormone health: Prioritize sleep (7–9 h), stress control, muscle building, anti-inflammatory nutrition, and toxin minimization; avoid cannabis and nicotine (both sexes), which impair gametes and increase miscarriage risk.
Evidence-supported preconception supplements: Begin a prenatal (with folate), CoQ10, omega-3 fatty acids, and vitamin D; for male partners, add L‑carnitine (± zinc/selenium). Consider low-dose melatonin (1–3 mg) for sleep/inflammation preconception, then stop in pregnancy.
Clinical nuances: Egg freezing/IVF do not deplete ovarian reserve; stop combined OCPs 3–6 months before trying to learn ovulation, remove levonorgestrel IUD ~6 months before attempting conception, and avoid Depo‑Provera if planning pregnancy within 1–2 years. Selective, emerging tools (e.g., GLP‑1s in insulin resistance/inflammation, intrauterine PRP for implantation failure) show promise; ovarian PRP and red light remain investigational.
Clinical Insight
Replace the “fail‑first” model with an early, data‑driven approach: normalize AMH screening and ovulation/luteal‑phase tracking for reproductive‑age women to surface problems sooner and tailor timely lifestyle, medical, or procedural interventions that can materially improve outcomes.
Actionable Takeaway
At routine visits for women who might want children, offer AMH testing and brief ovulation‑tracking education, and initiate a 60–90‑day preconception plan: sleep 7–9 h; avoid cannabis/nicotine and NSAIDs outside menses; start prenatal (folate), CoQ10 (200–400 mg/day), omega‑3 (1–2 g/day EPA+DHA), vitamin D per level; counsel partners to add L‑carnitine (≈2 g/day); reassess promptly if luteal phase <11 days, cycles irregular, age ≥35, or ≥2 pregnancy losses.
12. The Human Upgrade: Biohacking for Longevity & Performance
CDC Director Jim O’Neill on Fixing America’s Broken Food Policy : 1449
Published: 2026-04-14
URL: Listen Here
Summary
Acting CDC Director Jim O’Neill outlines a pivot in U.S. food policy toward whole foods and away from ultra‑processed, grain‑heavy patterns, alongside active trials reassessing saturated fats. He details federal investments in causal aging biomarkers via ARPA‑H, broader acceptance of AI and wearables (with consent) in care, a renewed CDC focus on infectious diseases, support for GLP‑1s in obesity management, and a review of vitamin D limits. Several points reflect evolving policy announcements described in the interview.
Key Takeaways
HHS/CDC leadership reports newly announced U.S. dietary guidelines that emphasize whole, minimally processed foods, reduce reliance on grains and ultra-processed foods, and affirm that meat and full‑fat dairy can fit into a healthy diet; randomized controlled trials on saturated fats are underway.
The government is prioritizing replication and rigor, including a $144M ARPA-H initiative to develop and FDA‑validate causal biomarkers of aging to enable surrogate endpoints for prevention and longevity therapies.
CDC is refocusing on infectious disease and highlights recent collaborations that contained Ebola (DRC) and Marburg (Ethiopia), while rebuilding public trust via transparency and focus.
There is openness to testing non‑pharmaceutical and biohacking innovations (e.g., ozone therapy) with the same scientific standards, and expanded use of wearables and AI for early detection and clinical decision support, with strong emphasis on privacy and informed consent.
GLP‑1 receptor agonists are supported as effective tools for obesity when paired with nutrition and fitness, vitamin D upper‑limit recommendations are under review, and school meals are viewed as a high‑leverage point for improving national nutrition.
Clinical Insight
Expect a policy shift in federal nutrition guidance—toward whole, minimally processed foods with adequate protein and without blanket avoidance of saturated fat/full‑fat dairy—which, combined with GLP‑1 use where appropriate, can reshape counseling and management of obesity and cardiometabolic disease.
Actionable Takeaway
Update nutrition counseling now: guide patients to prioritize whole foods and minimize ultra‑processed/refined grains, target 1.2–1.6 g/kg/day protein, individualize recommendations on saturated fat based on cardiometabolic risk, and routinely measure 25‑OH vitamin D with supplementation as needed under monitoring.
13. The Human Upgrade: Biohacking for Longevity & Performance
1 Cup Every Morning Helped Me Lose 100 Pounds (Drink THIS) : 1452
Published: 2026-04-19
URL: Listen Here
Summary
This episode is a first‑person narrative promoting butter/MCT coffee, intermittent fasting, and a high‑fat, low‑grain approach while labeling common nutrition beliefs as myths and de‑emphasizing exercise for fat loss. It reflects popular biohacking perspectives but provides limited primary evidence; clinicians may encounter patients adopting these strategies and should contextualize them within current guidelines and individualized risk assessment.
Key Takeaways
Host Dave Asprey attributes losing over 100 pounds to starting mornings with “butter coffee” (grass‑fed butter + MCT oil) and practicing intermittent fasting, emphasizing satiety, steady energy, and reduced cravings.
He presents nine “myths” he believes hinder weight loss: saturated fat is harmful; low‑fat diets are healthy; calories‑in/calories‑out drives weight change; frequent small meals boost metabolism; all vegetables are beneficial (citing anti‑nutrients in some); whole grains are healthy; fruit is universally healthy (warns about fructose); breakfast is essential; and exercise is the primary tool for fat loss.
Asprey advocates prioritizing saturated fats from grass‑fed animal sources and coconut oil, avoiding trans fats and processed seed/vegetable oils, minimizing grains and high‑fructose fruits, and selecting lower anti‑nutrient vegetables.
He claims mold/mycotoxins in some coffees drive jitters and poorer tolerance, recommending “clean” coffee; he also argues diet quality and fasting outweigh exercise for fat loss and warns that overtraining may elevate cortisol.
The episode is largely anecdotal and promotional, referencing his books and commercial products; specific primary research citations supporting many claims are not provided.
Clinical Insight
Patients may inquire about high‑fat morning beverages and time‑restricted eating to curb hunger and aid weight management; clinicians should individualize guidance and, if trialed, monitor cardiometabolic risk (e.g., LDL‑C/apoB, glycemia, liver enzymes) given that several assertions—especially high saturated fat intake and broad avoidance of plant foods/grains—diverge from prevailing evidence‑based guidelines.
Actionable Takeaway
When patients ask about “butter coffee” or intermittent fasting, offer a short, supervised 2–4 week trial of time‑restricted eating (e.g., 14–16 hour daily fast) focused on minimally processed foods; advise non‑caloric morning beverages in higher‑risk patients, track hunger/weight/glucose, and recheck lipids as indicated before making longer‑term changes.
14. The Human Upgrade: Biohacking for Longevity & Performance
Jason Fung: 3 Rules to Lose 50 Pounds Without Ever Counting a Calorie : 1453
Published: 2026-04-21
URL: Listen Here
Summary
Jason Fung contends that contemporary obesity is driven primarily by hedonic and conditioned hunger magnified by ultra-processed foods and pervasive eating cues, not by a simple excess of calories. He outlines three rules—ditch ultra-processed foods, reintroduce fasting windows, and engineer environments—to lower hunger and make weight loss sustainable, positioning GLP‑1 medications as appetite-lowering tools to use alongside real‑food and behavior change.
Key Takeaways
Hunger has three distinct drivers—homeostatic (physical), hedonic (pleasure), and conditioned (cue-driven/social)—and the latter two dominate modern overeating.
Ultra-processed foods are engineered to maximize reward and minimize satiety (rapid absorption, texture modifiers, emulsifiers, flavor enhancers), amplifying hedonic and conditioned hunger independent of calories.
Sustained weight loss rarely results from calorie restriction alone; approaches that reduce hunger (diet quality, meal timing/fasting, environmental redesign) work better. GLP-1 receptor agonists help mainly by suppressing appetite but require concurrent habit change for durability.
Fung’s three golden rules: eliminate ultra-processed foods; include consistent fasting periods (reduce meal frequency/snacking); and redesign schedules/environments to remove eating cues and food noise.
Behavioral and mindset tools—such as extinction and counter-conditioning, eating only at a table, and reframing ultra-processed items as “not food”—can deprogram conditioned hunger and reduce cravings.
Clinical Insight
For patients with obesity, target hunger biology and conditioned cues rather than caloric math: assess and modify diet quality (real food over ultra-processed), structure meal timing (fasting windows), and reshape social/environmental triggers; consider GLP-1 agents to reduce appetite while concurrently coaching durable nutrition and behavioral skills.
Actionable Takeaway
At the next visit, screen for the three hunger types and initiate a 4‑week protocol: eliminate ultra-processed foods; eat 2–3 real‑food meals within an 8–10‑hour window with no calories between; and remove eating cues (no eating in the car/TV, keep snacks out of sight). If on a GLP‑1, pair with nutrition/behavioral coaching to build lasting habits.
15. The Human Upgrade: Biohacking for Longevity & Performance
Jason Fung: 3 Rules to Lose 50 Pounds Without Ever Counting a Calorie : 1453
Published: 2026-04-21
URL: Listen Here
Summary
This episode reframes obesity care around managing hunger biology and learned cues rather than prescribing calorie restriction. Fung explains how ultra-processed foods and ubiquitous food cues amplify hedonic and conditioned hunger, and outlines three practical rules—cut UPFs, add fasting windows, and redesign environments—to align physiology and behavior. GLP-1 medications can help by suppressing hunger, but sustained success depends on concurrent nutrition and behavioral retraining.
Key Takeaways
Overeating is primarily a hunger problem—not a calorie problem—with three contributors: homeostatic (physical), hedonic (pleasure-driven), and conditioned (cue-driven) hunger; in modern environments, conditioned and hedonic hunger dominate.
Ultra-processed foods are engineered to maximize reward (rapid absorption, intense flavors, optimized texture) while minimizing satiety, reinforcing both hedonic and conditioned hunger and driving habitual overconsumption.
Calorie restriction alone fails long term because physiology adapts and hunger intensifies; focusing on reducing hunger signals via food quality, structured fasting, and behavioral strategies is more sustainable.
GLP-1 receptor agonists reduce hunger and can enable weight loss, but durable results require concurrent learning of real-food eating patterns and environment/cue redesign to prevent relapse when medications stop.
Dr. Fung’s three golden rules: (1) eliminate ultra-processed foods; (2) establish consistent fasting windows and stop constant snacking; (3) redesign schedules and environments to reduce food cues, using counterconditioning and extinction to retrain conditioned hunger.
Clinical Insight
For sustained weight loss, clinicians should target the biology and behavior of hunger—especially conditioned and hedonic drivers—by replacing ultra-processed foods with real foods, implementing time-based fasting windows, and modifying environments/cues; pharmacologic appetite suppression (e.g., GLP-1 RAs) can be an adjunct but must be paired with nutrition and behavior change to maintain results.
Actionable Takeaway
Start a two-week intervention: advise patients to remove ultra-processed foods from home/work, eat 2–3 whole-food meals daily with adequate protein and natural fats, avoid between-meal snacks, and keep a 12–14-hour overnight fast; restrict eating to a table (not cars/TV) and replace evening snacking with unsweetened tea to extinguish conditioned cues, then reassess hunger/craving patterns at follow-up.
16. The Human Upgrade: Biohacking for Longevity & Performance
Jason Fung: 3 Rules to Lose 50 Pounds Without Ever Counting a Calorie : 1453
Published: 2026-04-21
URL: Listen Here
Summary
Dr. Jason Fung reframes weight loss around hunger biology and environment, arguing that hedonic and conditioned hunger—amplified by ultra-processed foods and pervasive cues—drive overeating more than true physical hunger. Sustainable management targets appetite regulation (real food, fasting windows, environment design, behavioral techniques) and may incorporate GLP-1 therapy as a tool while patients build lasting dietary and behavioral skills.
Key Takeaways
Obesity is driven by three types of hunger—homeostatic (physical), hedonic (pleasure-driven), and conditioned (social/cue-driven)—with conditioned and hedonic hunger now dominating due to environment, marketing, and constant food cues.
Chronic calorie restriction fails long-term because appetite and hormones (e.g., insulin, GLP-1 pathways) govern intake and expenditure; GLP-1 receptor agonists work by lowering hunger but require concurrent nutrition and behavior change for durable results.
Ultra-processed foods (UPFs) are engineered to maximize reward (rapid absorption, flavor enhancers, emulsifiers/texturizers) and minimize satiety, amplifying ‘food noise,’ cravings, and overeating; additives like carrageenan/xanthan gum can worsen mouthfeel-driven intake and may irritate the gut.
Fung’s three golden rules: (1) eliminate UPFs in favor of real, nutrient-dense foods; (2) ensure an adequate fasting window and stop constant snacking; (3) redesign schedule and environment (eat at a table, avoid eating while driving/TV, manage cues) to reduce conditioned hunger.
Behavioral strategies such as counterconditioning (pairing cravings with aversive imagery) and extinction/substitution (e.g., tea instead of snacks while watching TV), plus a mindset shift to view UPFs as “not food,” help deprogram conditioned eating.
Clinical Insight
Effective obesity care centers on diagnosing and treating hunger dysregulation (hedonic and conditioned drivers) and hormonal responses to food, not prescribing simple calorie restriction; prioritize removal of ultra-processed foods, structured fasting/eating windows, and environmental cue control, using GLP-1s as adjuncts to reduce hunger while patients learn durable eating behaviors.
Actionable Takeaway
Start a 2–4 week ‘real food + fasting’ trial: remove all ultra-processed items and sweetened/‘diet’ beverages; eat 2–3 real-food meals daily emphasizing protein and natural fats; maintain a 12–16 hour overnight fast with no snacking; and restrict eating to a table—then reassess hunger, satiety, and weight at follow-up.
17. The Human Upgrade: Biohacking for Longevity & Performance
Inside Kambo: Poison, Purging, and The People Who Swear By It : 1455
Published: 2026-04-24
URL: Listen Here
Summary
This episode examines Kambo’s traditional origins, modern ceremonial use, administration, peptide-based mechanisms, safety profile, and preliminary human outcomes. It highlights practical risk-reduction (especially electrolyte management), underscores the paucity of rigorous clinical data, and discusses sustainability and training standards relevant to clinicians advising patients exploring Kambo.
Key Takeaways
Kambo (frog skin secretion from Phyllomedusa bicolor) is applied via superficial skin burns and is not a classical psychedelic; it induces a rapid, intense 20–30 minute experience marked by flushing, tachycardia, nausea/vomiting, sweating, shaking, transient facial swelling (“frog face”), and possible bowel movements or syncope.
Traditional Amazonian use centered on ‘hunting magic’ (adaptogenic effects like heightened perception and stamina); modern practice emphasizes ritual, trauma work, and broad wellness aims, with anecdotal utility reported for pain, autoimmune issues, infections, metabolic disease, and addiction.
Pharmacology involves at least 27 peptide analogs across eight families (e.g., opioid-receptor–active and vagal-acting peptides, antimicrobial peptides) producing vascular, GI, autonomic, and possible antipsychotic effects; however, rigorous human research on the full Kambo cocktail is sparse.
Safety hinges on preventing hyponatremia from overhydration (especially when stacked with low-salt ayahuasca dieta/fasting) and supervising to mitigate aspiration and falls; with careful screening, electrolyte management, and close monitoring, serious adverse events appear uncommon.
Emerging data (practice datasets, a post-session survey, and a prospective human study pending publication) suggest improvements in mood, mindfulness, happiness, pain, and fatigue after Kambo; sustainability and standardization remain challenges, spurring conservation work and attempts to characterize/synthesize peptide mixtures.
Clinical Insight
Kambo is a peptide-rich, non-psychedelic intervention with meaningful autonomic, GI, antimicrobial, and opioid-receptor effects that may yield short-term improvements in mood, mindfulness, and pain—yet its safe application in practice depends primarily on rigorous screening and proactive electrolyte management to prevent hyponatremia.
Actionable Takeaway
If a patient plans to undergo Kambo, counsel them to avoid overhydration: use salted fluids or oral electrolyte solution (e.g., add 1/4–1/2 tsp sea salt per liter of water), avoid low-salt/fasting protocols and stacking with ayahuasca within 24–48 hours, and ensure the session is supervised by a trained practitioner who monitors for syncope/aspiration.
18. Huberman Lab
Male Roles, Obligations and Options for Building a Fulfilling Life | Scott Galloway
Published: 2026-04-27
URL: Listen Here
Summary
This episode examines modern male roles and well-being, advancing a positive masculinity framework (provider–protector–procreator plus service) and concrete habits that build purpose, skills, and relationships. It highlights Big Tech’s role in compulsive use and isolation, advocates for mentorship and national service, and outlines policy levers (antitrust, algorithmic liability, age-gating) and personal behaviors clinicians can reinforce to improve mental health and social outcomes.
Key Takeaways
Galloway proposes a constructive masculinity code—provider, protector, procreator—augmented by service and the goal of creating “surplus value” (giving more than one takes).
Practical plan for struggling young men: reclaim screen time; train hard (≥3x/week); work outside the home (~30 hrs/week when feasible); engage weekly in team/service groups; and practice graded social “approaches,” embracing rejection as a skill-builder.
Big Tech and algorithmic feeds foster compulsive phone use, isolation, and polarization; policy remedies discussed include antitrust actions, algorithmic liability (Section 230 reform), and age-gating social media for minors.
Male mentorship and (ideally) national service are framed as high-yield solutions to purpose, skill development, and social cohesion—especially critical for boys lacking an involved male role model.
Societal/economic context matters: wealth transfer from young to old, higher-ed gatekeeping, and limited vocational on-ramps are linked to male underachievement and relationship/fertility headwinds; clinicians should recognize porn overuse as an under-researched, potentially demotivating behavior, while alcohol/THC can be net harmful or helpful depending on context and use patterns.
Clinical Insight
For young and midlife men, social isolation coupled with compulsive digital use (better conceptualized as an OCD-like compulsion loop than simple ‘dopamine hits’) is a potent driver of anxiety, depression, and suicidality; brief clinical screening and counseling that redirect time toward structured exercise, out-of-home work/school, service/mentorship, and graded real-world social engagement can meaningfully improve mental health and functioning.
Actionable Takeaway
In visits with adolescent and young adult males, add a 4-point screen—1) daily screen time and app limits, 2) exercise ≥3 days/week (resistance and/or endurance), 3) hours spent working or studying outside the home, 4) weekly group/service participation—then prescribe a 2–4 week trial to reallocate at least 8 hours/week from phone use to those activities and provide a mentorship or Big Brothers Big Sisters referral if a stable male role model is lacking.
19. The Human Upgrade: Biohacking for Longevity & Performance
The Strangest Thing I Do Every Morning for 15 Minutes | Brad Pitzele : 1458
Published: 2026-04-30
URL: Listen Here
Summary
This episode outlines how EWOT and red/near-infrared light therapy can be mechanistically complementary: exercise-driven hyperoxia improves oxygen delivery while PBM increases mitochondrial oxygen demand and nitric oxide–mediated microvascular perfusion. The approach targets endothelial and mitochondrial dysfunction implicated in fatigue, chronic inflammation, and recovery limitations, with a practical protocol of 15 minutes of EWOT followed by immediate PBM. Few specific clinical trials were cited during the conversation; recommendations were largely mechanistic and experiential.
Key Takeaways
Exercise with Oxygen Therapy (EWOT) delivers ~93% oxygen during 10–15 minutes of light-to-moderate exercise using a concentrator and large reservoir bag, leveraging exercise-induced increases in ventilation, heart rate, vasodilation, and pressure gradients to drive oxygen deeper into tissues than resting oxygen supplementation.
Chronic inflammation and endothelial dysfunction impair microcirculation (pseudo-hypoxia) even when pulse oximetry is normal; swollen endothelial cells and less-flexible RBCs limit capillary oxygen delivery, pushing cells toward anaerobic metabolism, ROS production, and a self-reinforcing inflammatory loop.
Red/near-infrared photobiomodulation (PBM) enhances mitochondrial function by increasing oxygen demand and releasing nitric oxide for vasodilation; stacking PBM immediately after EWOT (when circulation and tissue oxygen levels are elevated) amplifies outcomes (energy, sleep, pain, recovery).
A practical stack advocated: ~15 minutes of EWOT followed immediately by 10–20 minutes of red/NIR light (multiple red and NIR wavelengths) targeted to symptomatic areas or whole body to pair oxygen supply with mitochondrial uptake.
Potential use cases discussed include fatigue, long-COVID/lung injury, endothelial and microvascular dysfunction, ‘anaerobic’ infections (e.g., Lyme), and detox support; the episode’s claims were primarily mechanistic and experiential, with few specific trials cited.
Clinical Insight
Tissue-level hypoxia from microvascular/endothelial dysfunction can persist despite normal SpO2; combining EWOT to enhance oxygen delivery with photobiomodulation to increase mitochondrial oxygen utilization and nitric oxide–mediated perfusion may help break cycles of low energy, inflammation, and impaired recovery.
Actionable Takeaway
For appropriate patients, trial a stacked protocol: 10–15 minutes of moderate EWOT (reservoir-fed ~93% FiO2) followed immediately by 10–15 minutes of red/NIR photobiomodulation (e.g., 620–660 nm and 800–1050 nm) targeted to key regions (e.g., lungs, neck/shoulders, lower limbs), while monitoring HR/BP/SpO2 and tracking functional markers (symptoms, 6MWT/VO2 proxy, and if available pulse wave velocity). Screen for contraindications to high FiO2 and follow oxygen safety protocols.
20. The Human Upgrade: Biohacking for Longevity & Performance
The Strangest Thing I Do Every Morning for 15 Minutes | Brad Pitzele : 1458
Published: 2026-04-30
URL: Listen Here
Summary
This episode explores how EWOT and red/near-infrared light target complementary sides of cellular energetics: EWOT boosts oxygen delivery during exercise, while photobiomodulation increases mitochondrial oxygen use and nitric oxide signaling. By addressing endothelial/microcirculatory dysfunction and mitochondrial inefficiency—common in aging and chronic disease—the combined approach may enhance energy, recovery, and vascular health, with practical protocols feasible at home.
Key Takeaways
Exercise with Oxygen Therapy (EWOT) uses a concentrator and large reservoir to deliver ~93% oxygen during 15 minutes of moderate exercise, leveraging exercise-induced vasodilation and pressure gradients to drive oxygen deeper into hypoxic tissues.
Aging and chronic illness often feature microcirculatory dysfunction and endothelial swelling that block red blood cells from reaching capillaries, creating tissue-level “pseudo-hypoxia” despite normal pulse oximetry; mitochondria then shift to low-yield anaerobic metabolism with more inflammatory byproducts.
Red/near-infrared light (photobiomodulation) complements EWOT by increasing mitochondrial oxygen demand and efficiency (e.g., cytochrome c oxidase effects) and by promoting nitric oxide–mediated vasodilation, improving energy production and microvascular function.
Stacking protocol: complete a 15-minute EWOT session, then immediately apply red/near-IR light (10–15 minutes) to capitalize on elevated circulation and oxygen availability; simultaneous use is possible but less practical.
Discussed benefits include improved energy, sleep, pain, skin quality, recovery, and potential support in conditions with microvascular/mitochondrial dysfunction (e.g., Lyme, post-viral/long-COVID lungs), along with practical access to home EWOT systems and broad-spectrum red/IR devices.
Clinical Insight
Tissue hypoxia from microvascular and endothelial dysfunction can persist with normal SpO2 and underlies many chronic symptoms; combining strategies that enhance oxygen delivery (EWOT) with those that increase mitochondrial oxygen utilization and nitric oxide–driven vasodilation (red/near-IR light) may restore cellular energy and improve function in select patients.
Actionable Takeaway
For appropriately screened patients, implement a stack 3–5 times weekly: 15 minutes of EWOT at moderate exertion using a reservoir-fed concentrator (~93% O2), followed immediately by 10–15 minutes of red/near-IR photobiomodulation directed to priority regions (e.g., thorax for lung issues or large muscle groups); track response via symptoms (energy, sleep, pain) and, when available, vascular metrics (e.g., pulse wave velocity).
21. The Human Upgrade: Biohacking for Longevity & Performance
The Strangest Thing I Do Every Morning for 15 Minutes | Brad Pitzele : 1458
Published: 2026-04-30
URL: Listen Here
Summary
This episode explains how EWOT and red/near‑infrared light therapy can be combined to address mitochondrial dysfunction and microcirculatory ‘pseudo-hypoxia’ that underlie many chronic symptoms. The discussion emphasizes endothelial health, nitric oxide–mediated vasodilation, arterial stiffness (pulse wave velocity), and the lung’s role in detoxification, offering a practical sequencing strategy (EWOT, then PBM) to enhance energy, recovery, and tissue oxygenation. Limitations: the conversation is expert opinion–heavy and promotional in parts, and does not cite specific peer‑reviewed studies.
Key Takeaways
Exercise with oxygen therapy (EWOT) uses a concentrator and large reservoir (~93% O2) to deliver high oxygen flow during 10–15 minutes of moderate exercise, leveraging exercise-induced vasodilation and pressure gradients to drive oxygen deeper into tissues.
Stacking red/near-infrared photobiomodulation (PBM) immediately after EWOT exploits elevated circulation and oxygen availability to increase mitochondrial oxygen demand and efficiency, enhancing energy production, recovery, pain relief, and potentially sleep, skin, and sexual function via nitric oxide signaling.
Endothelial health and microcirculation are central: inflammation causes endothelial swelling and reduced RBC deformability, creating ‘pseudo-hypoxia’ (normal SpO2 but poor tissue oxygenation) that shifts mitochondria to inefficient anaerobic metabolism and a pro-inflammatory ‘doom loop.’
Arterial stiffness is an aging biomarker (e.g., pulse wave velocity); exercise and PBM can increase nitric oxide, improve vasodilation, and may support arterial flexibility and downstream tissue oxygenation.
Lungs are major detox organs (~70% of toxin elimination); adequate oxygen is required for biotransformation and repair. EWOT may support recovery in post-viral/lung injury states by improving cellular oxygenation and mitochondrial energy needed for healing.
Clinical Insight
Sequenced therapy—EWOT to rapidly elevate tissue oxygen supply followed immediately by PBM to raise mitochondrial oxygen demand—can help overcome tissue-level ‘pseudo-hypoxia,’ restore aerobic metabolism, and improve microcirculatory function in patients with chronic inflammation, endothelial dysfunction, or post-illness fatigue.
Actionable Takeaway
Implement a clinic protocol: 10–15 minutes of EWOT (reservoir-fed ~93% O2) at moderate intensity (elevated HR/respiratory rate) followed within 5 minutes by 10–20 minutes of PBM (combined red ~630–680 nm and near-infrared ~800–1050 nm) targeted to symptomatic regions (e.g., thorax for lung, large muscle groups, or generalized exposure). Monitor SpO2/HR/BP, start with conservative dosing, and track outcomes (e.g., 6MWT, symptom scores, VO2 max trend, pulse wave velocity/microvascular assessments). Screen for photosensitizing meds and cardio-pulmonary contraindications.
22. The Human Upgrade: Biohacking for Longevity & Performance
Eat These Foods + Spices for 8 Weeks To Get 3 Years Younger | Kara Fitzgerald : 1461
Published: 2026-05-05
URL: Listen Here
Summary
This episode highlights clinical and mechanistic evidence that diet rich in methyl donors and polyphenols—supported by foundational lifestyle practices—can reverse epigenetic age within weeks, with nutrients doing the ‘heavy lifting.’ It also explores the frontier of Yamanaka factor biology and PRC2-linked ‘programmatic’ aging, proposing that select polyphenols may partially mimic reprogramming effects. Limitations include multimodal design (potential confounding), reliance on specific clocks, and that ‘Yamanaka mimetic’ strategies are largely preclinical.
Key Takeaways
An 8-week randomized controlled dietary and lifestyle program emphasizing methyl-donor foods and polyphenol-rich ‘methylation adaptogens’ reduced biological age by over three years on the Horvath epigenetic clock in healthy middle-aged men; subsequent analysis suggested nutrients—especially dense polyphenols—were the primary drivers.
The protocol featured 7–11 cups/day of fruits, vegetables, herbs, and spices; methylation-supportive foods (e.g., leafy greens, eggs, beets, liver); and included meditation, sleep hygiene, and exercise, with the control group’s exercise likely making exercise effects a wash.
Polyphenols (e.g., EGCG from green tea; culinary herbs like rosemary, oregano, marjoram, thyme; and targeted options like urolithin A) may modulate gene expression and epigenetic marks; supplements can layer on top of diet for therapeutic dosing, though diet provides synergistic ‘information’ not captured by single compounds.
Emerging work on Yamanaka factors and polycomb repressive complex 2 (PRC2) suggests a ‘programmatic’ component of aging; early evidence indicates caloric restriction and potentially select polyphenols could act as ‘Yamanaka mimetics’ to nudge youthful epigenetic programs (largely preclinical at present).
First-generation clocks (e.g., Horvath) may capture aspects of programmatic aging; newer measures (e.g., DunedinPACE) are useful for tracking pace of aging. Case reports indicate women can also achieve meaningful bioage improvements with similar nutrition-forward protocols.
Clinical Insight
A targeted, food-first intervention emphasizing methyl-donor nutrients and high–polyphenol intake—augmented by basic lifestyle practices—can measurably and rapidly lower epigenetic age; in this cohort, the nutritional components appeared to account for most of the effect.
Actionable Takeaway
Implement an 8-week methylation-supportive nutrition plan (7–11 cups/day of diverse plants and polyphenol-rich herbs/spices; plus methyl donors like leafy greens, eggs, beets, and liver), alongside meditation and sleep hygiene; consider layering targeted polyphenol and metabolic supplements (e.g., EGCG, urolithin A, alpha‑ketoglutarate, sodium butyrate) as appropriate, and measure epigenetic age (e.g., Horvath/DunedinPACE) pre- and post-intervention to assess impact.
23. Huberman Lab
Essentials: Compulsive Behaviors & Deep Brain Stimulation | Dr. Casey Halpern
Published: 2026-05-07
URL: Listen Here
Summary
Dr. Casey Halpern outlines how compulsive behaviors arise from dysregulated cortico-striatal reward circuits and how neuromodulation—DBS, TMS, and MRgFUS—can be leveraged to treat refractory cases, with immediate efficacy in movement disorders and growing promise in psychiatry. The episode emphasizes personalized, symptom-evoked targeting and the integration of invasive recordings, noninvasive tools, and machine learning to advance precision therapies for OCD, addiction, and eating disorders.
Key Takeaways
Deep brain stimulation (DBS) and MR-guided focused ultrasound (MRgFUS) can precisely modulate small brain regions; DBS provides adjustable electrical therapy via implanted electrodes, while MRgFUS enables incisionless ablation—both are highly effective for tremor and are being explored for psychiatric indications.
Obsessive-compulsive disorder (OCD) involves dysregulation of cortico-striatal circuits, especially the ventral striatum/nucleus accumbens, which gate reward-seeking versus compulsive behaviors; similar circuitry underlies addiction and binge-eating.
First-line OCD treatments include SSRIs/tricyclics and exposure and response prevention (ERP) therapy; about 30% remain symptomatic, and in severe refractory cases, DBS or capsulotomy yields roughly 50% response rates but often with residual symptoms—highlighting the need for more precise, symptom-specific targeting.
Noninvasive neuromodulation is advancing: TMS is FDA-approved for depression, OCD, and nicotine addiction; MRgFUS is FDA-approved for essential tremor and tremor-dominant Parkinson’s disease, with research into modulatory ultrasound and blood–brain barrier opening; stereo-EEG (sEEG) is being leveraged to define better targets for psychiatric diseases.
Emerging approaches seek to detect and interrupt pathologic urges (e.g., craving/obsession cells) using intraoperative recordings, lab-based mood/craving provocation paradigms, and machine learning—aiming for closed-loop, personalized interventions; awareness helps less severe cases but is often insufficient for the most refractory patients.
Clinical Insight
Compulsive behaviors across OCD, addiction, and binge-eating share a core dysfunction in ventral striatal reward/limbic circuits (notably the nucleus accumbens); targeted and personalized circuit modulation—guided by symptom-evoked neural signatures—offers a path to improve outcomes beyond current ~50% response rates from conventional DBS/lesional approaches.
Actionable Takeaway
For patients with OCD who remain symptomatic after adequate SSRI/tricyclic trials and ERP, refer to a specialized neuromodulation center to evaluate FDA-cleared transcranial magnetic stimulation (TMS) for OCD and to discuss candidacy and expectations for investigational DBS/capsulotomy in severe, treatment-refractory cases.
24. Huberman Lab
Essentials: Compulsive Behaviors & Deep Brain Stimulation | Dr. Casey Halpern
Published: 2026-05-07
URL: Listen Here
Summary
This episode outlines how compulsive behaviors and OCD arise from dysregulated cortico–striatal–limbic circuits and how neuromodulation—from TMS to DBS and MRI-guided focused ultrasound—is being applied and refined to treat severe, refractory cases. It emphasizes circuit-specific targeting (e.g., ventral striatum/nucleus accumbens), closed-loop detection of craving/obsession signals, and the roles of ERP and pharmacotherapy as first-line treatments. Note: As an Essentials excerpt, procedural details and specific trial outcomes are summarized at a high level.
Key Takeaways
Deep brain stimulation (DBS) delivers targeted electrical stimulation via implanted leads; transient effects (e.g., brief laughter or panic) reveal proximity to limbic circuits and have informed psychiatric applications beyond movement disorders.
Obsessive-compulsive disorder (OCD) and related compulsive/impulsive syndromes involve hyperactive prefrontal/orbitofrontal regions and ventral striatal circuits (notably the nucleus accumbens) that gate reward and compulsion; circuit-informed targeting is central to therapy development.
First-line OCD care includes SSRIs or clomipramine (tricyclics) and exposure and response prevention (ERP); ~30% remain refractory, and current surgical options (DBS or capsulotomy) achieve about a 50% responder rate, with residual symptoms common.
Noninvasive neuromodulation is advancing: TMS is FDA-cleared for depression, OCD, and smoking cessation; MRI-guided focused ultrasound is FDA-approved for tremor and is being explored for modulatory (non-ablative) applications and potential psychiatric targets.
Closed-loop paradigms combining invasive recordings (e.g., stereo-EEG/DBS) with symptom or mood provocation can identify ‘craving/obsession’ signals (e.g., for binge eating) to personalize stimulation, while awareness-based therapies help many but often fail in the most severe, treatment-resistant cases.
Clinical Insight
Compulsive and impulsive disorders are circuit-based conditions of cortico–striatal–limbic networks; precise, and increasingly closed-loop, neuromodulation targeting the ventral striatum/nucleus accumbens can provide meaningful benefit for severe, treatment-resistant patients, while TMS offers an FDA-cleared, less invasive option for select indications.
Actionable Takeaway
Establish a referral pathway to a specialty center (functional neurosurgery/psychiatry) for patients with treatment-refractory OCD to discuss neuromodulation options—offer an FDA-cleared TMS trial first when available, and consider DBS or capsulotomy evaluation (or clinical trials) if nonresponsive.
25. The Human Upgrade: Biohacking for Longevity & Performance
Pandemic Fever Is BACK, Testosterone and Brain Tumors, Rabies, and Dog Flu : 1463
Published: 2026-05-08
URL: Listen Here
Summary
This episode synthesizes emerging signals in oncology and infectious disease: new data suggesting physiologic testosterone may restrain glioblastoma behavior, alongside multiple zoonotic threats (Influenza D, canine coronavirus HuPn-2018, Andes hantavirus) and a temporary disruption to U.S. rabies testing. The unifying message is proactive risk management—know patients’ biologic baselines (e.g., hormones), reinforce first-line defenses (mucosal immunity, sleep, stress), and act quickly when exposure windows are short (rabies, hantavirus).
Key Takeaways
NIH-funded Cleveland Clinic research reported that low testosterone may drive glioblastoma stemness and invasion, whereas restoring physiologic testosterone reduced tumor growth by ~38% and improved survival in models—challenging assumptions that lower androgens universally reduce cancer risk.
CDC has paused certain testing (including rabies), creating potential 1–2 week diagnostic delays; because rabies PEP is time-critical, suspected exposures warrant same-day ER initiation of prophylaxis without waiting for lab confirmation; ensure pets are vaccinated and consider pre-exposure prophylaxis when traveling to endemic regions.
A U.S. Supreme Court one-week stay preserved telehealth access to mifepristone pending rapid review; the legal reasoning could set precedents affecting FDA authority, telehealth, and access to therapies such as compounded peptides and bioidentical hormones.
University of Florida researchers highlighted two zoonotic risks: Influenza D circulating in U.S. cattle and a canine coronavirus (HuPn-2018) that has jumped to humans; no vaccines exist and population immunity is minimal—reassess raw milk risk and reduce close pet-lick exposure while strengthening mucosal immunity (sleep, stress control, vitamin D, zinc, fermented foods).
Andes hantavirus cases linked to a cruise ship off the Canary Islands underscore that this American strain can spread person-to-person and causes severe pulmonary syndrome with high case fatality; recognize early symptoms (fever, myalgias, abrupt fatigue) and pursue urgent evaluation after plausible exposure.
Clinical Insight
Maintaining normal physiologic testosterone may suppress glioblastoma aggressiveness by limiting tumor stemness and invasion, suggesting clinicians should consider comprehensive hormonal assessment—especially in men—when evaluating brain tumor biology and overall oncologic risk, while recognizing these are emerging data that do not alone warrant changes to standard cancer therapy without oncology guidance.
Actionable Takeaway
For any patient with a credible rabies exposure (e.g., bat contact, wild carnivore bite), initiate post-exposure prophylaxis immediately and do not wait for laboratory confirmation—verify current turnaround times at your state lab and proactively counsel patients traveling to endemic regions about pre-exposure vaccination and prompt care-seeking.
26. Huberman Lab
Essentials: Compulsive Behaviors & Deep Brain Stimulation | Dr. Casey Halpern
Published: 2026-05-07
URL: Listen Here
Summary
This episode reviews how neurosurgical and noninvasive neuromodulation tools can modulate cortico–striatal–limbic circuits driving compulsive and impulsive behaviors, with a focus on OCD, addiction, and binge eating. It emphasizes current standards (SSRIs/tricyclics and ERP), the limitations of outcomes in severe, refractory cases, and the promise of symptom-locked, circuit-guided targeting—potentially enabling future noninvasive, scalable treatments.
Key Takeaways
Deep brain stimulation (DBS) and MR-guided focused ultrasound (MRgFUS) can rapidly and powerfully modulate brain circuits; while established for tremor and Parkinson’s disease, these tools are being adapted to target limbic circuits implicated in compulsive and impulsive behaviors (e.g., OCD, addiction, binge eating).
OCD is best understood along a spectrum; first-line treatments include SSRIs/tricyclics and exposure and response prevention (ERP), yet ~30% remain refractory. For severe cases, DBS or capsulotomy yield about a 50% responder rate, often with residual symptoms—highlighting the need for more precise, symptom-locked targeting.
Compulsion and impulsivity share cortico-striatal-limbic circuitry (prefrontal/orbitofrontal cortex to basal ganglia/ventral striatum, especially nucleus accumbens) that gates reward seeking; identifying ‘craving/obsession-related’ neural signals intraoperatively and in lab paradigms is enabling symptom-specific neuromodulation.
Noninvasive neuromodulation is expanding: TMS is FDA-approved for depression, OCD, and nicotine addiction; MRgFUS is FDA-approved for tremor and is being explored for circuit modulation and blood–brain barrier opening. Stereo-EEG methods from epilepsy are informing circuit mapping for psychiatric indications to guide future noninvasive targets.
Improving patient awareness can help, but the most severe patients often remain refractory despite high awareness; combining rigorous circuit-guided neuromodulation with behavioral therapies and exploring AI/digital phenotyping to forecast high-risk states may provide scalable, clinically meaningful advances.
Clinical Insight
Compulsive and impulsive behaviors frequently arise from dysregulation within a shared cortico–striatal–limbic circuit—particularly the ventral striatum/nucleus accumbens—and targeted, symptom-linked neuromodulation (invasive now, potentially noninvasive later) can acutely alter these states, offering a path forward for patients with severe, treatment-resistant OCD and related conditions.
Actionable Takeaway
For patients with moderate-to-severe, treatment-resistant OCD (failed adequate SSRI/clomipramine trials and ERP), discuss risks/benefits and refer to a specialty center for consideration of neuromodulation—TMS (therapeutic and circuit-probing), DBS (e.g., ventral capsule/ventral striatum) or capsulotomy—and potential enrollment in circuit-mapping/SEEG-informed trials, while maintaining evidence-based behavioral therapy.
27. The Human Upgrade: Biohacking for Longevity & Performance
Pandemic Fever Is BACK, Testosterone and Brain Tumors, Rabies, and Dog Flu : 1463
Published: 2026-05-08
URL: Listen Here
Summary
This episode synthesizes timely health stories: a Cleveland Clinic/NIH report that normal testosterone may suppress glioblastoma stemness, a CDC testing pause that heightens urgency for immediate rabies PEP, legal moves affecting mifepristone telehealth access, and zoonotic threats from influenza D, canine coronavirus, and Andes hantavirus. The unifying theme is proactive risk management—optimizing hormonal and immune baselines and taking swift action after high-consequence exposures. Some details are host-reported and specific study links were not provided in-episode, which may limit independent verification.
Key Takeaways
NIH-funded Cleveland Clinic research reported that physiologic testosterone suppresses glioblastoma stemness and invasion; in models, restoring normal T reduced tumor growth by ~38% and improved survival—challenging the assumption that lower testosterone uniformly lowers cancer risk.
The CDC pause in rabies (and some other) testing is causing 1–2 week diagnostic delays; because post-exposure prophylaxis (PEP) must start promptly (≈10 days) and symptomatic rabies is nearly 100% fatal, suspected exposures warrant same-day ER care, with pets kept current on vaccines and travelers to endemic regions considering pre-exposure prophylaxis.
A temporary U.S. Supreme Court stay preserved mail/telehealth access to mifepristone pending further action—raising broader implications for courts influencing FDA-approved protocols and telehealth access across other therapies (e.g., compounded peptides, bioidentical hormones).
University of Florida researchers flagged two zoonotic risks: influenza D circulating in U.S. cattle and a canine coronavirus strain (CCoV-HuPn-2018) previously detected in humans; neither has established population immunity or vaccines, underscoring practical steps to bolster mucosal immunity and apply caution with raw milk and close pet contact (e.g., face-licking).
An outbreak of Andes hantavirus linked to a cruise near the Canary Islands highlights that this strain can spread person-to-person and causes severe HPS with high mortality; early symptoms (fever, myalgias, rapid-onset fatigue) after plausible exposure should prompt urgent evaluation and explicit hantavirus consideration.
Clinical Insight
Emerging evidence suggests hypogonadism may promote glioblastoma aggressiveness via androgen receptor signaling; in appropriate male patients, clinicians should assess total and free testosterone and avoid non-indicated androgen deprivation—coordinating closely with oncology before modifying cancer-related hormonal management.
Actionable Takeaway
For suspected rabies exposures (e.g., bat contact/bites), initiate CDC-recommended post-exposure prophylaxis immediately without waiting for laboratory confirmation, given current testing delays and the near-100% fatality once symptoms begin.
28. Huberman Lab
Essentials: Understanding & Controlling Aggression
Published: 2026-05-14
URL: Listen Here
Summary
This episode explains the neural circuitry of aggression, emphasizing VMHvl Esr1+ neurons and how aromatized estrogen, stress hormones, and photoperiod interact to gate aggressive behaviors. It reframes testosterone’s role, highlights rapid circuit-level switches between mating and attack, and offers practical strategies—light exposure, heat, selective supplementation—to modulate aggression. As an Essentials recap, some dosing specifics and full trial details are referenced from prior episodes or literature rather than provided exhaustively in-audio.
Key Takeaways
Aggression comprises distinct forms (reactive, proactive, indirect) and is generated by coordinated neural circuits—most critically estrogen receptor–expressing neurons in the ventromedial hypothalamus (VMHvl)—acting as fixed action patterns rather than isolated brain regions.
Testosterone does not directly cause aggression; its aromatization to estrogen within the brain activates VMHvl Esr1+ neurons to drive attack behaviors in both males and females.
Context strongly gates aggression: short photoperiods, elevated cortisol, and low serotonin increase the likelihood that estrogen will trigger aggression; long photoperiods (more daylight) mitigate this effect via changes in melatonin, dopamine, and stress hormones.
Optogenetic activation of VMHvl Esr1+ neurons can rapidly switch behavior (e.g., from mating to attack) and recruits downstream periaqueductal gray (PAG) circuits that organize motor patterns such as biting and limb striking.
Practical levers to reduce aggressive tendencies include lowering cortisol (morning sunlight exposure, sauna/hot baths; cautious, short-term ashwagandha) and, in ADHD, adjunct acetyl-L-carnitine has evidence for reducing aggressive/impulsive episodes in a randomized controlled trial.
Clinical Insight
Aggression propensity is a state-dependent output of hypothalamic circuits (VMHvl Esr1+), gated by steroid signaling and the stress–neurochemical milieu; assessing and modulating contextual factors—especially cortisol/photoperiod and serotonergic tone—can meaningfully alter aggressive behavior beyond simplistic attributions to testosterone or mood states.
Actionable Takeaway
Implement a structured morning light protocol for irritable or seasonally worsened aggression: advise 10–30 minutes of outdoor sunlight exposure within 1 hour of waking, daily for 2–4 weeks, to lower cortisol and shift neuromodulators toward reduced reactivity; reassess symptoms and add heat therapy (e.g., 20-minute sauna or hot bath sessions) as needed.
29. The Human Upgrade: Biohacking for Longevity & Performance
Semen Switch, Chewing Gum, Creatine Cheat, Cancer Plants, and Bedtime Risk : 1467
Published: 2026-05-15
URL: Listen Here
Summary
This episode reviews studies on creatine’s cognitive support under acute sleep loss, microplastic exposure from chewing gum, the cardiovascular risks of irregular bedtimes, plant alkaloid biosynthesis enabling anticancer drug discovery, and a reversible nonhormonal male contraceptive target. The unifying theme is that seemingly neutral habits or exposures can carry measurable biological effects, with particular clinical relevance for circadian consistency. Limitations: the transcript lacks formal citations and may contain transcription errors in compound or organism names; verify primary sources before changing practice.
Key Takeaways
A single moderate dose of creatine (~14 g) preserved up to ~12% more cognitive performance during 21 hours of sleep deprivation in a double-blind crossover trial; women and people with lower baseline brain creatine (e.g., vegetarians/vegans) appeared to benefit more.
Chewing gum (synthetic and products marketed as natural/plastic-free) shed hundreds to ~3,000 microplastic fragments per stick into saliva; detected polymers included polyethylene and polystyrene, highlighting a previously underrecognized exposure source.
Objectively measured irregular bedtimes combined with shorter sleep were associated with about double the risk of major cardiovascular events over a decade in a Finnish cohort, underscoring the clinical importance of sleep timing regularity.
UBC researchers mapped a chromosome-level genome and decoded the biosynthetic pathway for a rare spirooxindole alkaloid (Mitraphylene) implicated in anti-tumor and anti-inflammatory activity, enabling potential scalable bioproduction; this is an early-stage drug discovery lead, not a recommendation to use kratom or related supplements.
Cornell researchers demonstrated reversible, nonhormonal male contraception in mice by inhibiting the testis-specific protein BRDT with JQ1: spermatogenesis stopped during treatment and fertility recovered after cessation with healthy offspring; translational safety and long-term effects require further study.
Clinical Insight
Sleep regularity—not just duration—is a modifiable risk factor linked to major cardiovascular events; counseling patients to maintain consistent bedtimes should be incorporated into cardiovascular risk reduction strategies.
Actionable Takeaway
Ask patients to set and adhere to a fixed 90-minute bedtime window every day (including weekends) and reassess sleep timing variability after 4–8 weeks; for higher-risk individuals, consider actigraphy or validated wearable data to quantify and address irregularity.
30. The Human Upgrade: Biohacking for Longevity & Performance
Semen Switch, Chewing Gum, Creatine Cheat, Cancer Plants, and Bedtime Risk : 1467
Published: 2026-05-15
URL: Listen Here
Summary
This episode reviews new research spanning acute creatine use for sleep-deprivation resilience, unrecognized microplastic exposure from chewing gum, the cardiovascular risks of irregular sleep timing, plant-derived drug discovery via kratom alkaloid biosynthesis, and a reversible, non-hormonal target for male contraception. The themes emphasize measurable exposures and behaviors that affect health now (e.g., sleep regularity, microplastics) and pipeline advances likely to influence future oncology and reproductive therapeutics.
Key Takeaways
Acute creatine supplementation (~10–15 g monohydrate) preserved up to ~12% more cognitive performance during 21 hours of sleep deprivation in a double-blind crossover trial; benefits appeared greater in women and those with lower baseline brain creatine (e.g., vegetarians/vegans).
Chewing gum—both synthetic and products marketed as “natural” or “plastic-free”—shed hundreds to ~3,000 microplastic fragments per stick into saliva during chewing, adding a largely unrecognized exposure source.
Objectively measured irregular bedtimes combined with short sleep duration were associated with approximately double the risk of major cardiovascular events over a decade, underscoring circadian regularity as a modifiable risk factor.
UBC researchers mapped the genome of Mitragyna parvifolia and decoded the biosynthetic pathway for the alkaloid mitraphylline, enabling potential bioreactor-scale production; this is a drug discovery pipeline advance, not evidence that kratom treats cancer.
Pharmacologic inhibition of the testis-specific protein BRDT with JQ1 in mice produced a reversible, non-hormonal “on–off” switch for spermatogenesis, restoring fertility after treatment cessation and suggesting a viable target for male contraception.
Clinical Insight
Sleep timing regularity is an independent, modifiable cardiovascular risk factor: patients with highly irregular bedtimes and short sleep had roughly double the rate of major cardiovascular events when sleep timing was objectively measured, supporting routine assessment and counseling on circadian consistency.
Actionable Takeaway
Incorporate a brief sleep-timing screen (e.g., ask about bedtime variability and weekend ‘social jetlag’) and counsel patients to maintain a consistent 90-minute bedtime window across all days, including weekends, as part of cardiovascular risk reduction.
31. Huberman Lab
How to Overcome Social Anxiety | Dr. Nick Epley
Published: 2026-05-18
URL: Listen Here
Summary
Evidence converges that small, authentic social exchanges meaningfully improve mental and physical well-being. Social anxiety is best treated with real-world exposure that recalibrates overly pessimistic beliefs about others. Voice and in-person modalities humanize and increase perceived intelligence relative to text, suggesting clinicians and clients should favor voice/in-person touchpoints when feasible.
Key Takeaways
Real-world social exposure—not simulation—reduces social anxiety by updating inaccurate predictions about rejection; people are helped and accepted more often than they expect.
Brief, everyday interactions (greetings, small talk, sincere compliments) reliably lift mood; the biggest well-being gain comes from moving from no contact to some contact.
Voice conveys rich mental-state cues that humanize others; compared with text, speaking increases perceived intelligence and mutual understanding, especially across divides.
We routinely misread others due to cognitive biases (egocentrism, stereotyping, correspondence bias); testing assumptions through low-stakes bids to connect corrects many misinferences.
Short periods of acting more extraverted increase positive affect for most people, including introverts; small, repeated real interactions function as effective ‘social prescriptions’.
Clinical Insight
Loneliness and social isolation are modifiable risk factors linked to increased all-cause mortality, cardiometabolic burden, and dysregulated stress physiology. For social anxiety, graded in vivo exposure is an evidence-based intervention that changes maladaptive social predictions (e.g., overestimating rejection) rather than merely dampening arousal.
Actionable Takeaway
Implement a 2-week graded social exposure plan: daily, initiate one brief, real interaction (e.g., greet a neighbor or cashier, ask a small favor, offer a sincere compliment); log predicted outcome vs. actual outcome to capture expectancy violations. Each week, add 2–3 short voice calls (not texts) to trusted contacts. Progressively increase depth or duration as mispredictions correct.
32. Huberman Lab
How to Overcome Social Anxiety | Dr. Nick Epley
Published: 2026-05-18
URL: Listen Here
Summary
Dr. Nick Epley discusses how everyday social connections—especially those using richer cues like voice and eye contact—improve mental and physical health, and how misbeliefs about others’ interest create avoidant behavior and social anxiety. He outlines evidence that real-world exposure updates these misbeliefs, highlights the health costs of isolation, and offers practical ways to cultivate frequent, small interactions that enhance well-being.
Key Takeaways
Real-world exposure (not simulation) is the most effective way to reduce social anxiety because it updates mistaken beliefs about rejection and others’ responses.
People reliably underestimate how much others want to engage and help; silence and phone use are often misread as disinterest, leading to missed opportunities for connection.
Richer communication channels—especially voice (and eyes/visual behavior when available)—convey the ‘presence of mind,’ reduce dehumanization, and improve mutual understanding compared with text-only exchanges.
Small, daily social interactions (brief greetings, compliments, short conversations) measurably improve mood and health; moving from no contact to some contact yields the biggest well-being gains.
Acting more extroverted (within one’s comfort) increases positive affect across the introversion–extroversion spectrum; building simple, repeatable social habits is key.
Clinical Insight
For patients with social anxiety, the core therapeutic lever is belief change achieved through graded, in vivo exposure to real social interactions—patients learn (through experience) that positive or neutral responses are far more common than anticipated, which reduces avoidance and improves functioning.
Actionable Takeaway
Prescribe a graded real-world exposure plan: ask the patient to complete one brief, low-stakes social action daily (e.g., greet a stranger, ask for minor help, offer a sincere compliment), log the outcome, and review weekly to challenge overestimated rejection fears and reinforce corrective learning.
33. The Human Upgrade: Biohacking for Longevity & Performance
The Biblical Anti-Aging Fruit That Scientists Are Obsessed With : 1470
Published: 2026-05-21
URL: Listen Here
Summary
This episode details the discovery-to-clinic journey of urolithin A (Mitopure) as a nutritional mitophagy activator that enhances mitochondrial function, with human data showing improved immune cell composition and mitochondrial gene expression after 4 weeks and topical studies demonstrating better collagen signaling and wrinkle reduction. It provides dosing guidance and highlights the limitations of pomegranate-derived precursors, underscoring UA’s relevance for clinicians integrating mitochondrial-targeted interventions into healthy aging care.
Key Takeaways
Urolithin A (Mitopure), a gut-derived postbiotic from pomegranate ellagitannins, activates mitophagy and improves mitochondrial function; preclinical work showed ~45% lifespan extension in C. elegans and ~40% endurance gains in aged mice.
In a human study (Nature Aging), adults aged 50–70 taking 1 g/day for 4 weeks had increased naïve CD8 T cells and NK cells, decreased inflammation, and upregulated mitochondrial gene expression/function in immune cells.
Muscle biopsy studies show increased expression of mitochondrial genes after 4 weeks of oral urolithin A at 500–1,000 mg/day, helping define an effective daily dose (≥500 mg) for clinical use.
Topical urolithin A improved skin biology and appearance: increased collagen-related gene expression, >10% reduction in UV-induced inflammation, and statistically significant wrinkle reduction by 8 weeks (signals as early as 2 weeks).
Only ~30–40% of people can convert pomegranate polyphenols into urolithin A; direct UA supplementation provides reliable exposure versus juice/extracts (which also add sugar/oxalates).
Clinical Insight
Urolithin A is an evidence-based mitophagy activator with early clinical signals in muscle and immune aging; consistent supplementation (≥500 mg/day) can improve mitochondrial-related biomarkers and immune cell profiles in midlife and older adults, offering a practical adjunct for healthy aging strategies.
Actionable Takeaway
For eligible adults focused on longevity or mitochondrial health, consider urolithin A 500 mg daily (up to 1,000 mg) taken consistently for 2–4 months before assessing response; avoid relying on pomegranate extracts due to variable microbiome conversion, and optionally pair with topical UA for skin benefits.
34. The Human Upgrade: Biohacking for Longevity & Performance
The Biblical Anti-Aging Fruit That Scientists Are Obsessed With : 1470
Published: 2026-05-21
URL: Listen Here
Summary
This episode details the discovery-to-clinic journey of urolithin A as a mitophagy activator that targets a root mechanism of aging: mitochondrial dysfunction. The discussion reviews preclinical and human data showing improvements in muscle mitochondrial gene expression, immune cell composition, and topical skin outcomes, positioning urolithin A as a practical, evidence-supported addition to longevity care. (Note: Some study specifics were summarized at a high level in the transcript and may lack full methodological details.)
Key Takeaways
Urolithin A (commercialized as Mitopure/Timeline) is a postbiotic derived from pomegranate ellagitannins via gut microbes; only ~30–40% of people naturally convert, so a standardized supplement ensures reliable delivery at effective doses.
Mechanism of action is mitophagy activation (selective recycling of dysfunctional mitochondria), with preclinical data showing ~45% lifespan extension in C. elegans and ~40% greater running endurance in aged mice.
Human data: 4 weeks of 500 mg–1 g/day increased mitochondrial gene expression in skeletal muscle biopsies; clinical benefits are most apparent with consistent daily use over 2–4 months.
Immune health (Nature Aging study): adults aged 50–70 taking 1 g/day for 1 month had increased naive CD8 T cells and NK cells and reduced inflammatory signaling.
Topical urolithin A increased collagen-related gene expression, reduced post-UV skin inflammation (~10%), and produced statistically significant reductions in fine lines/wrinkles by 8 weeks; L’Oréal is collaborating to incorporate the ingredient based on shared research.
Clinical Insight
Standardized urolithin A is a clinically investigated mitophagy activator that can improve mitochondrial biomarkers and favorably shift immune cell populations in older adults within weeks, supporting its use as a safe, adjunctive tool to enhance healthspan beyond traditional approaches (e.g., NAD precursors, rapamycin).
Actionable Takeaway
For adults over ~50, consider a monitored 8–12 week trial of urolithin A at 500–1000 mg orally once daily; track patient-reported energy/exercise tolerance and optionally inflammation markers (e.g., CRP) or simple functional tests, and avoid substituting pomegranate extract due to variable microbiome conversion.
35. Huberman Lab
Build Muscle, Great Posture & Resilience to Injury | Jeff Cavaliere
Published: 2026-05-25
URL: Listen Here
Summary
This episode emphasizes that “small” accessory work—especially for the glute medius, rotator cuff, neck, grip, and feet—makes the big lifts possible for decades by preventing pain and improving function. Cavaliere outlines practical screens (e.g., old‑man shoe/sock test) and brief, low‑equipment drills that clinicians and trainees can integrate alongside flexible programming and sensible nutrition to support long‑term health, performance, and injury resilience.
Key Takeaways
Small, often-neglected muscles and motor control (glute medius, rotator cuff, neck flexors/extensors, foot intrinsics) are foundational for pain-free longevity and enable progress on the big compound lifts.
A large share of nonsurgical low back pain reflects gluteal weakness and pelvic control deficits (e.g., Trendelenburg pattern) rather than spine pathology; targeted work (reverse hypers, wall ‘hip hike,’ banded hip rotation) can resolve symptoms and prevent recurrence.
Medial elbow pain during pulling is frequently a grip/hand position issue (overloading ring/pinky at the fingertips); using a knuckles-over-bar grip and loading the meat of the hand often eliminates symptoms.
Shoulder durability depends on external rotator strength and posture—train banded external rotation with the elbow pinned (towel cue), use face pulls, and avoid chronically elevated, internally rotated positions.
Programming principles: take safer/isolation movements to (or near) failure, avoid true failure on complex lifts, count indirect volume (e.g., biceps on back day), and use flexible scheduling (even ‘split the split’) rather than forcing a 7‑day template; pair with simple daily/weekly function tests (old‑man shoe/sock test, side‑plank with top-leg abduction) and sensible ‘clean omnivore’ nutrition.
Clinical Insight
For many patients with common musculoskeletal complaints (e.g., nonspecific low back pain, shoulder impingement symptoms, medial elbow pain), the primary driver is often weakness or poor motor control in adjacent or distal links of the kinetic chain (glute medius/pelvic control, rotator cuff external rotators, grip mechanics) rather than structural pathology—prioritizing targeted strengthening and technique cues can reduce pain, restore function, and decrease unnecessary imaging or surgical referrals.
Actionable Takeaway
For chronic, nonspecific low back pain, screen glute medius function (single‑leg stance/Trendelenburg sign) and prescribe a 5–7 minute, 3x/week accessory routine: wall ‘hip hike’/abduction (2–3 sets/side) plus reverse hypers or prone hip extension with a brief hold at peak contraction (2–3 sets). Reassess gait and pain after 2–4 weeks and progress to banded hip ER/IR as tolerated.
36. Huberman Lab
Essentials: The Science & Process of Healing from Grief
Published: 2026-05-28
URL: Listen Here
Summary
This episode reframes grief as a neurobiological remapping process across space, time, and closeness, emphasizing that yearning arises from motivation circuits rather than depression per se. It offers practical, physiology-informed tools—structured grieving sessions, vagal tone enhancement, and sleep/cortisol stabilization—to support adaptive progression through grief and reduce risk of complicated grief. Some imaging findings and animal-to-human links were discussed without full study citations in the episode.
Key Takeaways
The brain maps relationships across three braided dimensions—space, time, and closeness—and grief is the neuroplastic remapping that uncouples space/time predictions from an intact sense of attachment.
fMRI work highlights the inferior parietal lobule as a common code for physical distance, temporal spacing, and social closeness, while motivation/“yearning” circuits (e.g., nucleus accumbens) are prominently engaged in grief.
Individual differences in oxytocin signaling—particularly receptor density within reward/motivation circuits—help explain variability in the intensity and persistence of yearning during grief.
The Kübler-Ross stages are not universal; grief and depression share symptoms but are distinct processes with different neurobiological underpinnings.
Structured “rational grieving” (time-limited sessions that fully feel attachment while avoiding counterfactual thinking), supported by physiologic tools (enhancing vagal tone, stabilizing diurnal cortisol via morning light, prioritizing sleep/NSDR), promotes adaptive grieving and may reduce risk for complicated grief.
Clinical Insight
Effective grieving preserves the felt attachment while deliberately remapping space and time predictions; interventions that enhance vagal tone and normalize diurnal cortisol can facilitate this adaptive neuroplastic transition and help prevent complicated grief.
Actionable Takeaway
Schedule a daily 10–20 minute “rational grieving” session: intentionally feel your attachment to the deceased while actively avoiding counterfactual (“what if”) thoughts; before starting, perform 2–3 minutes of slow, exhale-emphasized breathing to increase vagal tone and stability during the session.
37. Huberman Lab
Peptides: The Science, Uses & Safety | Dr. Abud Bakri
Published: 2026-06-01
URL: Listen Here
Summary
The discussion frames peptides by receptor biology and evidence strength. Trial-backed metabolic peptides (GLP-1/GIP) contrast with research-stage compounds (e.g., BPC-157, thymic/epigenetic peptides) that lack rigorous human data. Emphasis is on clinical guardrails: verified sourcing, slow titration where applicable, and objective monitoring for efficacy and safety.
Key Takeaways
Prioritize peptides with defined receptors and robust human data (e.g., GLP-1 agonists); treat others with limited evidence (e.g., BPC-157, TB-4/Thymosin-β4, epithalon) as experimental.
BPC-157 shows promising animal data for GI and tissue repair but lacks high-quality human trials; safety, sourcing, and regulatory status are major concerns.
GLP-1/GIP agents (e.g., semaglutide, tirzepatide) deliver substantial, trial-proven weight and metabolic benefits when titrated slowly and paired with lifestyle support.
Thymic peptides and GH secretagogues may influence immune/body composition markers but require careful monitoring (e.g., IGF-1, glucose/insulin sensitivity) and medical oversight.
Quality control and legality matter: avoid gray-market products; verify compounding/pharmacy sources and monitor objective biomarkers.
Clinical Insight
Think pharmacology-first: confirm target, mechanism, human outcomes, and safety monitoring before considering any peptide, and avoid non-verified supply chains.
Actionable Takeaway
If using a GLP-1 agonist for weight management, start at the lowest dose, titrate every ~4 weeks as tolerated, maintain nutrition/resistance training, and monitor GI tolerance, hydration, and mood—under clinician supervision with pharmacy-verified products.
38. Health Longevity Secrets
Do We Actually Want to Live Forever? — David Donnelly (Director, Forever Young)
Published: 2026-06-02
URL: Listen Here
Summary
Filmmaker David Donnelly describes moving from skepticism to conviction that we’re in a true longevity revolution, highlighting epigenetic aging, biomarkers, and the outsized impact of lifestyle relative to genetics. The episode urges clinicians and the public to prioritize healthspan and the human context—purpose, mental health, and social connection—while navigating hype and emerging interventions with caution. Some statistics are presented conversationally without formal sourcing.
Key Takeaways
Biological age (captured by epigenetic methylation clocks like the Horvath clock) can diverge significantly from chronological age, and we can now track it with biomarkers.
Lifestyle appears to dominate the pace of aging—genes contribute a relatively small fraction (<10%)—so sleep, nutrition, movement, and social connection are central to longevity; even a 30-minute daily walk may markedly reduce chronic disease risk.
The longevity field spans pragmatic healthspan extension to speculative fronts such as epigenetic reprogramming and “age-looping”; while breakthroughs loom, current best gains come from fundamentals.
Healthspan, not just lifespan, should be the target; without addressing purpose, loneliness, and mental health, living longer could amplify suffering.
Hype and unregulated products are common; rely on trusted experts and institutions, use objective biomarkers judiciously, and be wary of miracle claims.
Clinical Insight
The most actionable clinical implication is that modifiable lifestyle and psychosocial factors (physical activity, sleep, diet quality, social connection/purpose) are the primary levers to slow biological aging and extend healthspan; validated biomarkers (including epigenetic clocks and standard labs) can help individualize, monitor, and motivate these interventions.
Actionable Takeaway
Integrate a brief longevity-focused check-in at routine visits: screen for physical activity (prescribe at least 30 minutes of brisk walking daily as tolerated), sleep, diet, loneliness/social isolation, and purpose; document baseline biomarkers (e.g., metabolic profile ± a validated biological age test when appropriate) to guide preventive care and follow-up.
39. The Second Opinion Podcast with Dr. Paul Kolodzik
EP 121- Why you need a Metabolic Health Review and what it will show you.
Published: 2026-06-04
URL: Listen Here
Summary
This episode argues for a targeted metabolic health review that moves beyond traditional screening by quantifying insulin resistance, refining lipid risk (including Lp(a)), and using coronary calcium scoring to detect early atherosclerosis. It emphasizes that GLP-1–induced weight loss is not synonymous with metabolic health and that lifestyle interventions remain foundational.
Key Takeaways
A comprehensive metabolic health review should include assessing insulin resistance using simultaneous fasting insulin and fasting glucose to calculate HOMA-IR, complemented by a short-term continuous glucose monitor (CGM) to evaluate glycemic patterns and spikes.
Cholesterol evaluation should go beyond standard panels to examine LDL particle characteristics and measure lipoprotein(a) to refine cardiovascular risk assessment.
Coronary artery calcium (CAC) scoring by noninvasive CT is a quick (≈1–2 minutes), low-cost screening tool for middle-aged adults—especially those with risk factors—to quantify plaque burden and guide further testing.
Weight loss from GLP-1 therapy improves health but does not automatically restore metabolic health; lifestyle modification remains essential, and GLP-1s are best used as an adjunct.
Highly processed, high-carbohydrate dietary patterns have driven obesity and diabetes in the U.S.; historic low-fat guidance was oversimplified, and the ‘French paradox’ notion of alcohol’s cardioprotection has not held up, though components like resveratrol were discussed.
Clinical Insight
Do not equate weight loss or standard labs alone with metabolic health—proactively measure insulin resistance (fasting insulin + glucose; HOMA-IR) and refine cardiovascular risk with LDL subfraction/Lp(a) testing and CAC scoring to detect disease earlier and individualize prevention.
Actionable Takeaway
Add a fasting insulin to routine fasting labs and calculate HOMA-IR for adults with metabolic risk; if elevated or glycemia is borderline, prescribe a 10–14 day CGM to visualize glycemic variability and tailor nutrition and therapy accordingly.
40. Huberman Lab
Essentials: Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams
Published: 2026-06-04
URL: Listen Here
Summary
This episode reframes depression and PTSD as circuit-level disorders amenable to rapid intervention through targeted neuromodulation and, in controlled settings, psychedelic-assisted therapy. Evidence highlights accelerated TMS producing fast remissions and convergent network changes observed with psilocybin and MDMA, while emphasizing safety, strict medical supervision, and the limited durability of ketamine. Some content reflects preliminary or open-label findings and anecdotal observations that require further controlled study.
Key Takeaways
Depression is the most disabling condition worldwide and is now recognized by the American Heart Association as a major risk factor for coronary artery disease; transcranial magnetic stimulation (TMS) over dorsolateral prefrontal cortex (DLPFC) demonstrates a measurable brain–heart pathway (via anterior cingulate/insula/amygdala to vagus/heart) that can modulate heart rate.
SSRIs benefit a subset of patients with depression, OCD, and anxiety but act slowly and do not support a simple “chemical imbalance” model; shifting to a circuit-based framework (psychiatry 3.0) emphasizes correcting dysfunctional neural networks.
Accelerated, targeted TMS (Stanford Neuromodulation Therapy/SAINT) using spaced, high-dose sessions over five days can induce rapid remission (≈60–90% across open-label and controlled studies) by restoring DLPFC control over cingulate/default-mode circuitry, with variable durability.
Psychedelic-assisted therapies show condition-specific promise: MDMA-assisted therapy yields clinically meaningful PTSD improvement in about two-thirds of participants with effects lasting to years; psilocybin demonstrates antidepressant effects (≈1/3 in blinded trials; higher in open-label) alongside convergent normalization of subgenual ACC–default mode network connectivity; ketamine’s benefit is typically shorter-lived (~7–14 days per infusion).
Emerging agents: Ibogaine can produce a prolonged, non-recreational “life review” with reported therapeutic gains but carries cardiac (QT) risk necessitating ECG screening; ayahuasca (oral DMT plus reversible MAOI) appears relatively safe in observational work, has antidepressant signals, and was associated with reduced recidivism in a Brazilian prison study, underscoring the need for controlled, medically supervised use.
Clinical Insight
Rapid, durable symptom relief in depression and PTSD can be achieved by normalizing dysfunctional brain circuits—particularly restoring DLPFC governance and reducing subgenual ACC–default mode coupling—using precisely targeted neuromodulation (accelerated TMS) or psychedelic-assisted therapy, marking a practical shift from neurotransmitter-centric models to circuit-focused interventions.
Actionable Takeaway
For patients with severe or treatment-resistant depression, refer to a center offering individualized, accelerated iTBS/TMS (SNT/SAINT) that delivers multiple sessions per day over five days, with a plan for follow-up/maintenance to support durability; reserve psychedelic-assisted therapies for regulated clinical trials or approved programs and counsel that ketamine’s benefits are typically short-lived.
41. The Human Upgrade: Biohacking for Longevity & Performance
How to Get Microplastics Out of Your Body | Mara Labs : 1478
Published: 2026-06-04
URL: Listen Here
Summary
This episode explores microplastic exposure, proposed cellular handling via lysosomes, and how stabilized sulforaphane may mobilize and enhance elimination of microplastics while broadly upregulating Nrf2-mediated detox (glutathione, glucuronidation, sulfation). The guests also discuss practical exposure mitigation, estrogen metabolite modulation, ASD data, and adjuncts like berberine and resveratrol/curcumin for AMPK/lysosomal biogenesis. Some claims—particularly on microplastics excretion—rely on preliminary or unpublished work and should be interpreted cautiously.
Key Takeaways
Emerging evidence suggests sulforaphane (in a stabilized, supplemental form) can mobilize intracellular microplastics via lysosomal exocytosis (“lysosomal surface translocation”) and facilitate elimination, with preliminary data indicating fecal excretion.
Sulforaphane robustly activates Nrf2/phase II detox pathways (glutathione synthesis and GST activity, glucuronidation, and sulfation), supporting clearance of diverse xenobiotics (e.g., benzene/airborne pollutants, BPA) and favorably shifting estrogen metabolism.
Real-world exposure reduction matters: major microplastic sources include indoor air, synthetic textiles (e.g., fleece), dryer lint, foam furniture/rugs, and thermal-paper receipts (BPA); mitigation includes HEPA filtration (especially in bedrooms) and choosing natural fibers.
Neurologic and metabolic signals: a randomized trial from Johns Hopkins found behavioral improvements in ASD with sulforaphane; users may note vivid dreams (consistent with increased BDNF). Berberine (separate agent) can improve glycemia and sleep but may cause hypoglycemia.
For periods of higher toxic load (e.g., rapid fat loss, air travel), timed use of sulforaphane alongside basic binders (separated by several hours) and sauna/fasting protocols may reduce symptom burden; evidence for microplastics elimination beyond blood mobilization is still limited and includes unpublished data.
Clinical Insight
Sulforaphane offers a practical, multi-pathway detoxification lever (Nrf2-driven phase II induction) that may help clinicians address modern environmental burdens—including microplastics and endocrine disruptors—while potentially improving estrogen metabolite profiles and neurobiologic resilience; early mechanistic and clinical data are encouraging, though some microplastics findings are preliminary/unpublished.
Actionable Takeaway
For patients with high environmental exposure or initiating weight loss, consider adding a high-quality, stabilized sulforaphane supplement (per label dosing) as part of an exposure-reduction plan (HEPA filter in bedroom; avoid thermal-paper receipts and synthetic textiles), timing it away from oral binders like charcoal by at least 2 hours and monitoring for sulfur sensitivity or hypoglycemia if also using berberine.
42. Health Longevity Secrets
EXPLAINER: Sleep Isn’t For Muscle Repair — Here’s What It’s Actually For
Published: 2026-06-04
URL: Listen Here
Summary
This episode reframes sleep from a muscle-repair adjunct to a primary neurologic and endocrine reset that underpins cognitive function, metabolic health, and hormonal balance. Short sleep rapidly degrades insulin sensitivity and sex hormone levels, while targeted thermoregulation offers a practical, evidence-aligned way to improve sleep architecture and downstream health.
Key Takeaways
Sleep’s dominant functions are neurological housekeeping (glymphatic waste clearance), memory consolidation, and endocrine recalibration; muscle protein synthesis proceeds largely independent of sleep architecture and timing.
During sleep, brain interstitial space expands by ~60%, enabling a cerebrospinal fluid flush that clears beta-amyloid and tau; this high-throughput glymphatic process requires deep slow-wave sleep and does not run efficiently when awake.
Disrupting the first slow-wave cycle blunts the night’s major growth hormone pulse; one week of ~5 hours/night reduces testosterone by ~10–15%, and four nights of 4 hours/night induces prediabetic insulin resistance in healthy adults.
Sleep restriction elevates evening cortisol, suppresses melatonin, increases ghrelin, and decreases leptin—driving hunger, impaired satiety, and worsened glucose control—mechanistically linking short sleep to weight gain despite constrained total energy expenditure.
Thermoregulation is a high-yield intervention: a hot bath/shower 60–90 minutes before bed plus a cool bedroom (65–68°F) shortens sleep latency and deepens slow-wave sleep, outperforming common supplements.
Clinical Insight
For clinicians, sleep should be framed and managed as a neuroendocrine therapy: protecting early-night slow-wave sleep and sufficient REM is essential for glymphatic clearance, memory consolidation, and maintenance of insulin sensitivity, growth hormone, and testosterone—effects that cannot be offset by training schedules or protein timing.
Actionable Takeaway
Advise patients to take a warm-to-hot bath or shower 60–90 minutes before bedtime and maintain a cool bedroom (65–68°F) to accelerate sleep onset and enhance slow-wave sleep depth.
43. The Human Upgrade: Biohacking for Longevity & Performance
Peptide Power Without Needles: Smarter Dosing for Longevity | Justin Kirkland : 1477
Published: 2026-06-02
URL: Listen Here
Summary
This episode reviews practical advances and pitfalls in peptide therapy—emphasizing quality control, safer/easier delivery (auto-injectors, microneedles, intranasal), and the importance of personalized response based on genetics and the microbiome. It highlights clinically useful classes (GH secretagogues, immune and repair peptides), common side effects, and dosing/storage considerations while cautioning against overhyped agents without supportive pharmacokinetics. Formal citations were not provided during the episode; references below align with topics mentioned.
Key Takeaways
Peptide quality and safety vary widely: residual trifluoroacetic acid (TFA) salts from synthesis and biologic endotoxins (e.g., LPS) can contaminate products; proper salt exchange to acetate and rigorous QC (HPLC/MS, 19F-NMR, endotoxin testing) are essential.
Dosing confusion is common when users reconstitute vials with variable volumes; standardized concentrations paired with reusable auto-injector pens can simplify accurate, repeatable at-home administration via telemedicine.
Needle-free delivery is advancing: microneedle patches (e.g., for BPC) can achieve systemic delivery with minimal sensation, and intranasal formulations with permeation enhancers can approximate injectable bioavailability for certain peptides (e.g., PT‑141).
Oral bioavailability is the exception, not the rule; select small peptides such as KPV, BPC-157, and Dihexa may retain activity orally due to limited enzymatic degradation, whereas most peptides require parenteral or alternative routes.
Clinical response is highly individualized and influenced by genetics and the microbiome; lack of effect may reflect host factors (e.g., nitric oxide pathway interference by gut microbes) rather than peptide inefficacy. Overhyped examples (e.g., short half-life follistatin without half-life extension) underscore the need for pharmacokinetic-aware selection.
Clinical Insight
Verified sourcing and analytical quality control (correct acetate salt, minimal residual TFA, and low endotoxin) plus standardized dosing/delivery often determine peptide safety and outcomes more than the specific peptide chosen.
Actionable Takeaway
When prescribing peptides, use a pharmacy/lab that supplies US-synthesized acetate-salt APIs with third-party HPLC/MS identity and endotoxin testing (and, when relevant, residual TFA by 19F-NMR), and standardize reconstitution and auto-injector dosing to eliminate ‘units’ confusion and reduce dosing errors.
44. The Human Upgrade: Biohacking for Longevity & Performance
Putin Longevity, Pancreatic Cancer Cure, AI Therapy, GLP-1 Breast Cancer... : 1479
Published: 2026-06-05
URL: Listen Here
Summary
This episode reviews emerging oncology signals (oncolytic virotherapy for pancreatic cancer; observational link between GLP-1 use and lower breast cancer odds), rising youth reliance on AI chatbots for emotional support, Russia’s large-scale longevity initiative, and the evidence gap between sauna and cold exposure. The overarching message is to prioritize interventions backed by strong human outcomes data (sauna) while pursuing trials to validate promising mechanistic or observational findings (e.g., GLP-1s in cancer risk).
Key Takeaways
An early safety study injecting engineered oncolytic viruses into pancreatic tumors (n=3) showed intratumoral replication, tumor lysis, and apparent immune activation even at low dose—an encouraging signal against notoriously treatment-resistant pancreatic cancer.
Approximately 19% of adolescents and young adults report using AI chatbots for emotional support; while some find it helpful, concerns include dependency, false reassurance, and potential delays in accessing qualified mental health care.
A Penn Medicine retrospective analysis of >111,000 women (ages 45–80; BMI ≥25) found GLP-1 exposure associated with ~30–35% lower odds of breast cancer; as observational data, it signals potential benefit via metabolic pathways but requires randomized trials to establish causality.
Russia reportedly launched a ~$26B state-backed longevity program (“New Health Preservation Technologies Initiative”) focusing on gene therapy, organ bioprinting, and xenotransplantation—advances may accelerate but could be limited by data opacity.
Long-term human cohort data strongly support frequent sauna use (≥4 sessions/week) for reduced cardiovascular and all-cause mortality, whereas cold exposure offers acute alertness and recovery benefits but lacks comparable longevity outcome evidence.
Clinical Insight
For risk reduction and healthy longevity, regular sauna therapy has robust long-term human outcome data (lower CVD and all-cause mortality at ≥4 sessions/week), whereas cold exposure should be viewed primarily as an acute performance/recovery tool pending comparable evidence.
Actionable Takeaway
Discuss sauna therapy with appropriate patients and, if no contraindications, help them implement a routine targeting ≥4 sessions/week (e.g., 15–20 minutes per session at a tolerable temperature), with counseling on hydration, heat intolerance, cardiovascular monitoring, and gradual acclimatization.
45. This Week in Cardiology
Jun 05 2026 This Week in Cardiology
Published: 2026-06-05
URL: Listen Here
Summary
This episode challenges reflexive, technology- or procedure-first approaches: IV flecainide appears highly effective for ED cardioversion in carefully selected CAD patients, yet most stable recent-onset AF can be safely managed with delayed cardioversion; sensor-driven HF monitoring failed to improve outcomes; modest weight loss alone did not change AF metrics; and prophylactic LAA excision without AF showed no benefit. The overarching message favors conservative, evidence-based strategies that prioritize patient education and judicious intervention.
Key Takeaways
In the FLECA-ED trial of ED cardioversion for new-onset AF with stable CAD and preserved EF, IV flecainide achieved 86% conversion at 6 hours vs 40% with amiodarone, with no acute VT and similar bradycardia; the study was small and not powered for safety, and CAST’s chronic proarrhythmia risk should not be overextrapolated to a single acute dose.
For hemodynamically stable recent-onset AF, a delayed “wait-and-see” strategy with rate control and reassessment is noninferior to immediate cardioversion and avoids unnecessary shocks; most patients spontaneously convert within 48 hours (RACE 7 ACWAS).
In HFrEF, a multisensor insertable cardiac monitor algorithm (Alleviate-HF) did not improve a hierarchical composite outcome and numerically trended worse vs usual care; prior CardioMEMS evidence remains equivocal, highlighting that alerts and complex workflows may not translate into outcome benefits.
An 8-month counselor-guided low-calorie program produced ~10% weight loss but did not improve AF symptoms, rhythm outcomes, or cardiometabolic markers in older patients with persistent AF (LUSE-AF), suggesting greater weight loss and comprehensive risk-factor management (e.g., sleep apnea, fitness, alcohol) may be required; GLP-1 agonists are promising for broader metabolic gains.
Prophylactic surgical left atrial appendage excision during valvular surgery in patients without AF (OPINION) did not reduce stroke/TIA/CV death at 1 year; routine closure in sinus rhythm is not supported pending larger ongoing trials (e.g., LEAPS), whereas LAAOS III supports closure only when AF is present in addition to anticoagulation.
Clinical Insight
For most stable, recent-onset AF presentations, immediate ED cardioversion is rarely necessary; a wait-and-see approach with rate control and appropriate anticoagulation is safe, often results in spontaneous conversion, avoids fear-amplifying procedural framing, and reserves intervention for the minority who remain in AF or become unstable.
Actionable Takeaway
Adopt a standardized ED pathway for recent-onset, hemodynamically stable AF: initiate rate control, start/continue anticoagulation per CHA2DS2-VASc, provide reassurance and clear return precautions, and arrange reassessment within 24–48 hours before attempting cardioversion; if chemical cardioversion is pursued in carefully selected CAD patients with preserved EF and no residual ischemia, consider flecainide (where available) over amiodarone while acknowledging limited safety power.
46. The Human Upgrade: Biohacking for Longevity & Performance
Putin Longevity, Pancreatic Cancer Cure, AI Therapy, GLP-1 Breast Cancer... : 1479
Published: 2026-06-05
URL: Listen Here
Summary
This episode reviews emerging fronts in cancer and longevity—from oncolytic viruses in pancreatic cancer and the potential cancer‑risk impact of GLP‑1 RAs, to the superior long‑term evidence for sauna versus cold exposure—while cautioning against adolescents’ reliance on AI chatbots for mental health. It also flags Russia’s large‑scale state investment in longevity technologies and its implications for global science. Limitations: several findings are preliminary or observational, and some sources were not formally cited in the episode.
Key Takeaways
An early safety study injecting an engineered oncolytic virus directly into pancreatic tumors (n=3) showed intratumoral replication, tumor cell lysis, and apparent immune activation even at low dose—suggesting feasibility in a treatment‑resistant cancer.
Survey data indicate ~19% of adolescents and young adults turn to AI chatbots when distressed (highest in ages 18–21), raising concern about dependency and delayed access to human mental health care.
A Penn Medicine retrospective cohort (>111,000 women, ages 45–80, BMI ≥25) found GLP‑1 receptor agonist exposure associated with ~30–35% lower odds of breast cancer; while observational, authors call for randomized trials and mechanisms may include improved insulin resistance and reduced inflammation.
Sauna use has robust long‑term human data linking higher frequency (≥4 sessions/week) to lower cardiovascular and all‑cause mortality; by contrast, cold exposure shows acute benefits with limited long‑term human outcomes despite mechanistic interest (e.g., RBM3).
The Wall Street Journal reports Russia’s ~$26B state longevity program (gene therapy, bioprinting, xenotransplantation) led by Maria Vorontsova and Mikhail Kovalchuk, highlighting potential scientific advances and concerns about data openness.
Clinical Insight
Addressing metabolic dysfunction (insulin resistance, chronic inflammation) may meaningfully reduce cancer risk—illustrated by observational data linking GLP‑1 RA use to lower breast cancer incidence—supporting integration of metabolic optimization into preventive and oncologic care while awaiting randomized trials.
Actionable Takeaway
When appropriate, counsel patients to incorporate regular sauna bathing as a longevity and cardiovascular risk‑reduction modality (e.g., ~4 sessions/week, 15–20 minutes at typical Finnish sauna temperatures), after screening for contraindications such as unstable cardiovascular disease, hypotension, dehydration, pregnancy, or heat intolerance.
47. The Human Upgrade: Biohacking for Longevity & Performance
Putin Longevity, Pancreatic Cancer Cure, AI Therapy, GLP-1 Breast Cancer... : 1479
Published: 2026-06-05
URL: Listen Here
Summary
This episode reviews emerging signals in oncology and longevity: early oncolytic virus results in pancreatic cancer, observational evidence linking GLP-1 use to lower breast cancer odds, and the strategic expansion of state-level longevity R&D in Russia. It also contrasts robust longitudinal data favoring frequent sauna use for longevity with the more limited human evidence base for cold exposure, and highlights risks of adolescents relying on AI chatbots for mental health support.
Key Takeaways
Early safety-dose intratumoral oncolytic virus therapy in pancreatic cancer reportedly induced tumor cell lysis and immune activation in three patients, suggesting a promising mechanism in a notoriously resistant malignancy.
Roughly 19% of adolescents and young adults report using AI chatbots for emotional support; while perceived as helpful, this may foster dependence and delay access to human-delivered mental health care.
A Penn Medicine retrospective cohort of ~111,000 women (ages 45–80; BMI ≥25) found GLP-1 receptor agonist exposure associated with ~30–35% lower odds of breast cancer versus non-users; causality is unproven and trials are needed.
Russia is reportedly launching a $26B state-backed anti-aging initiative (gene therapy, organ bioprinting, xenotransplantation), signaling accelerating investment in longevity science but raising concerns about data openness.
Long-term Finnish data link frequent sauna use (≥4 sessions/week) to lower cardiovascular and all-cause mortality; cold exposure offers acute benefits but lacks comparable long-term human outcomes data for longevity.
Clinical Insight
Optimizing metabolic health remains central to preventive oncology: observational data suggest GLP-1 receptor agonists may reduce breast cancer risk alongside benefits in weight, insulin resistance, and inflammation, but clinicians should interpret this as hypothesis-generating until randomized trials confirm causality.
Actionable Takeaway
For patients without contraindications, recommend regular sauna use as a primary longevity modality (target ≥4 sessions/week as tolerated) to support cardiovascular risk reduction and overall mortality benefits, with counseling on hydration, blood pressure monitoring, and heat safety.
48. The Human Upgrade: Biohacking for Longevity & Performance
I Drink Fat To Look Shredded (Lost 100lbs) : 1480
Published: 2026-06-07
URL: Listen Here
Summary
This episode centers on the host’s anecdotal claim that adding grass-fed butter and MCT oil to coffee enhances satiety, stabilizes energy, and promotes weight loss via ketone production and fat oxidation, alongside messaging about fat-soluble vitamin/mineral synergy. It outlines a simple routine (fat-based coffee, two meals, no grazing) and promotes several commercial products. No clinical trials or guidelines are cited, so any application to practice should be individualized and evidence-informed.
Key Takeaways
The episode advocates replacing sugar with “fat cubes” (grass-fed butter) plus MCT oil blended into coffee to provide steady energy, suppress appetite, and support weight loss—based largely on the host’s personal experience.
MCT oil is claimed to convert rapidly to ketones (brain fuel), while grass-fed butter provides butyrate, CLA, and fat-soluble vitamins; together they purportedly shift metabolism from glucose-burning to fat-burning with minimal insulin response.
The host emphasizes the synergy of minerals with fat-soluble vitamins D, A, K2, and E (plus magnesium) as a foundational stack for metabolic health and nutrient utilization.
A suggested routine is fat-based coffee in the morning with no sugar/carbs, followed by two meals (lunch and dinner) without grazing, to maintain satiety and remain in “fat-burning mode.”
Multiple commercial products and services are promoted (Danger Coffee, Viome testing, iRestore red-light devices, and a “DAKE and Minerals 101” stack), with no peer-reviewed studies or guidelines cited.
Clinical Insight
A fat-first, low-carbohydrate morning (e.g., coffee blended with butter and MCT oil) may enhance satiety and reduce snacking for some patients pursuing time-restricted feeding or ketogenic strategies; however, the episode’s claims are anecdotal and marketing-driven, so clinicians should individualize recommendations and monitor metabolic markers.
Actionable Takeaway
For appropriately selected patients interested in low-carb or time-restricted eating, consider a 2–4 week trial replacing sugary morning coffee with blended black coffee plus 1 tsp–1 Tbsp MCT oil and 1 tsp–1 Tbsp unsalted grass-fed butter (no added carbs), starting low to assess GI tolerance, while tracking hunger, total intake, weight, and relevant labs (lipids, glucose); discontinue if adverse effects or lipid derangements occur.
49. The Human Upgrade: Biohacking for Longevity & Performance
Putin Longevity, Pancreatic Cancer Cure, AI Therapy, GLP-1 Breast Cancer... : 1479
Published: 2026-06-05
URL: Listen Here
Summary
This episode spotlights emerging and established interventions across oncology, mental health, and longevity: early oncolytic virotherapy signals in pancreatic cancer, observational data linking GLP-1 use to lower breast cancer incidence, and strong evidence favoring regular sauna for mortality risk reduction over cold plunges for longevity. It also flags rising youth reliance on AI chatbots for emotional support and Russia’s state-scale investment in anti-aging technologies, underscoring opportunities and cautions for clinicians navigating fast-moving health innovations.
Key Takeaways
A first-in-human safety study injecting an engineered oncolytic virus directly into pancreatic tumors (n=3) showed intratumoral replication, tumor cell lysis, and an immune response even at low dose—an encouraging signal in a notoriously treatment-resistant cancer.
About 19% of adolescents and young adults report turning to AI chatbots for emotional support, with highest use in ages 18–21; hosts caution that chatbot engagement may foster dependency and delay access to real clinical care.
A large Penn Medicine retrospective cohort (~111,000 women, ages 45–80, BMI ≥25) found GLP-1 receptor agonist exposure associated with ~30–35% lower odds of breast cancer versus non-use; observational design precludes causality but aligns with metabolic risk-reduction mechanisms.
Russia reportedly launched a ~$26B state-backed longevity initiative (gene therapy, xenotransplantation, organ bioprinting), signaling sovereign-scale investment in anti-aging science but raising concerns about openness and data sharing.
Sauna use has robust long-term human data linking higher frequency (≥4 sessions/week) to reductions in cardiovascular and all-cause mortality, whereas cold plunges show mainly acute benefits (alertness, soreness, mood) with limited human longevity outcomes to date.
Clinical Insight
Improving metabolic health may meaningfully influence cancer risk: a large observational analysis suggests GLP-1 receptor agonist use in overweight/obese midlife-to-older women correlates with substantially lower breast cancer incidence, reinforcing metabolic dysfunction as an actionable cancer risk pathway and warranting randomized trials.
Actionable Takeaway
For appropriate patients without contraindications, recommend regular sauna bathing as a primary longevity modality—aim for four or more sessions per week—while using cold exposure chiefly for acute performance/recovery rather than long-term longevity benefits.
50. Huberman Lab
Eating for Better Sleep & Foods that Improve Metabolic Health | Dr. Marie-Pierre St-Onge
Published: 2026-06-08
URL: Listen Here
Summary
This episode details how sleep and nutrition dynamically co-regulate each other: inadequate sleep alters appetite hormones and reward pathways to promote overeating and poorer food choices, while dietary quality and meal timing directly influence sleep latency and deep sleep. Evidence supports Mediterranean/DASH-style eating, front‑loading calories, increasing fiber, and avoiding late eating as practical levers to improve sleep architecture and reduce cardiometabolic risk, with notable sex differences in hormonal responses to sleep loss.
Key Takeaways
Sleep and diet have a bidirectional relationship: insufficient sleep (even modest, chronic loss) increases caloric intake and alters food choices, while what and when you eat materially impacts sleep quality and architecture.
Under 5 nights of severe sleep restriction, men showed increased ghrelin (greater drive to eat) and women showed reduced GLP‑1 (reduced satiety), with ~300 kcal/day higher intake when allowed to eat ad libitum and heightened brain reward responses to food.
In free-living conditions, sustained but modest sleep curtailment (~1.5 h less/night for 6 weeks) worsened insulin resistance and raised blood pressure (especially in postmenopausal women), despite lab data showing cortisol/glucose/insulin can appear unchanged under tightly controlled, isocaloric conditions.
Diet composition and timing shape sleep: higher fiber intake was linked to more deep (slow‑wave) sleep, whereas higher saturated fat and refined carbohydrates reduced deep sleep and increased arousals; eating earlier and leaving ≥3 hours between last meal and bedtime improved sleep latency and depth.
Mediterranean/DASH-style patterns are associated with longer sleep and fewer insomnia symptoms; earlier daytime eating windows increased fat oxidation versus late eating, supporting front‑loading calories for better cardiometabolic and sleep outcomes.
Clinical Insight
Evaluating and counseling on both sleep and nutrition—specifically, meal timing (earlier eating and a ≥3‑hour pre‑bed fast) and dietary quality (higher fiber, lower saturated fat/refined sugars)—can measurably improve sleep architecture and cardiometabolic risk, with awareness of sex-specific appetite hormone changes under sleep loss (ghrelin ↑ in men, GLP‑1 ↓ in women).
Actionable Takeaway
Advise patients to shift most daily calories to earlier in the day and finish their last meal at least 3 hours before bedtime, emphasizing fiber‑rich foods and limiting saturated fat and refined carbohydrates to enhance deep sleep and improve metabolic health.
51. Docs Who Lift
Retatrutide Phase 3 Results: What the Data Actually Means
Published: 2026-06-08
URL: Listen Here
Summary
This episode breaks down the first phase 3 results for retatrutide, a triple-hormone agonist that delivers ~26–30% weight loss over 80–104 weeks with robust cardiometabolic improvements and meaningful benefits in sleep apnea and knee osteoarthritis pain. Early type 2 diabetes phase 3 data show near-normalization of A1c and double‑digit weight loss without background antihyperglycemics; clinicians should anticipate potent effects and adjust concomitant therapies accordingly. Note: parts of the TRIUMPH dataset remain preliminary pending full publication.
Key Takeaways
Retatrutide (triple GLP-1/GIP/glucagon agonist) produced bariatric-surgery–like weight loss in the TRIUMPH phase 3 obesity trial: ~19% (4 mg), ~26% (9 mg), and ~28% (12 mg) at 80 weeks; in an extension to 104 weeks, weight loss approached ~30% on 12 mg, with ~45% achieving ≥30% and ~25% achieving ≥35% total weight loss.
Cardiometabolic improvements were substantial: systolic BP fell ~11–12 mmHg, LDL ~20%, triglycerides ~41%, hsCRP ~64%, and 92–95% of those with prediabetes reverted to normoglycemia; sleep apnea events decreased ~60% and knee OA pain (WOMAC) dropped ~70%.
In the 40-week type 2 diabetes phase 3 study (monotherapy, no background antihyperglycemics), A1c fell by 1.7–1.9% (to ~6.0%) and weight by ~11.5–17%, with only a modest heart-rate rise (~2–3 bpm); placebo with intensive lifestyle reduced A1c ~0.8% and weight ~2.5%.
Tolerability resembled current incretin therapies: mostly GI events during titration (nausea ~25–40% depending on dose), low discontinuation rates (GI-related 2–4.5%; total 4–11% vs 5% on placebo), and signals for dizziness/hypotension likely from BP lowering; a possible UTI signal requires clarification.
Clinically, retatrutide may be prioritized for patients with more severe obesity or those plateauing on semaglutide/tirzepatide; if switching from tirzepatide, many may tolerate starting at 4 mg, though a conservative 2 mg start is reasonable, with proactive monitoring and medication de-intensification (especially antihypertensives).
Clinical Insight
Adding glucagon receptor agonism to GLP-1/GIP produces unprecedented, surgery-level weight loss with pronounced liver-centric lipid and blood-pressure benefits, necessitating active management of comorbidity medications (e.g., early down-titration of antihypertensives and close glycemic monitoring).
Actionable Takeaway
When initiating retatrutide, schedule a follow-up within 2–4 weeks to check blood pressure, heart rate, and glucose, and be prepared to proactively reduce antihypertensive and other glucose-lowering therapies while titrating slowly to minimize GI adverse effects.
52. The Peter Attia Drive
#395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer’s disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D.
Published: 2026-06-08
URL: Listen Here
Summary
This episode explains brain lipidology, emphasizing that CNS cholesterol metabolism is distinct from the periphery and depends on ApoE-containing HDL-like particles for neuronal supply, with ApoE genotype strongly influencing Alzheimer’s risk through cholesterol-driven effects on amyloid/tau. The guests review how statins, ezetimibe, omega‑3s, and CETP inhibition may impact brain cholesterol homeostasis and AD biomarkers, and how sterol biomarkers (desmosterol, 24S‑hydroxycholesterol) can inform therapy. Limitations: several mechanistic links are based on preclinical/observational data; 24S‑hydroxycholesterol testing is not widely available clinically.
Key Takeaways
Brain lipid metabolism is largely autonomous from the periphery: ApoB lipoproteins do not cross the blood–brain barrier; astrocytes/oligodendrocytes package cholesterol into ApoE-containing HDL-like particles that neurons take up via LDLR, LRP1, and SR-B1.
Neurons curtail de novo cholesterol synthesis after childhood to conserve ATP and depend on astrocyte-derived cholesterol (desmosterol pathway); excess neuronal membrane cholesterol shifts APP processing toward Aβ42 and tau, while neurons export surplus cholesterol as 24S‑hydroxycholesterol (a plasma marker of brain cholesterol efflux).
ApoE genotype governs brain HDL functionality and Alzheimer’s disease (AD) risk: E3 is neutral, E4 impairs lipid delivery/clearance at neuronal receptors, favoring amyloid and tau pathology; plasma desmosterol tracks CNS synthesis and 24S‑hydroxycholesterol (research-use) tracks neuronal cholesterol efflux.
Statins penetrate the brain (both lipo- and hydrophilic at steady-state) and overall show neutral or beneficial cognitive signals; rare ‘brain fog’ may reflect oversuppression of CNS synthesis—plasma desmosterol may help titrate therapy while achieving ApoB goals; 24S‑hydroxycholesterol falls with effective CNS cholesterol suppression in studies.
Adjuncts and emerging therapies: ezetimibe’s glucuronide metabolite may exert central effects; EPA/DHA reach the brain as lysophospholipids via specific transporters and higher omega-3 index correlates with better brain metrics observationally; CETP inhibition (obicetrapib) raises ApoA1/small HDL and has shown favorable movement in AD biomarkers in early analyses.
Clinical Insight
Lowering plasma ApoB/LDL-C does not deprive the brain of cholesterol because CNS cholesterol homeostasis is compartmentalized; in fact, optimizing neuronal cholesterol balance—particularly in ApoE4 carriers—may reduce amyloidogenic processing and improve brain health, with statins generally neutral-to-beneficial for cognition and sterol biomarkers (desmosterol, 24S‑hydroxycholesterol) offering mechanistic guidance.
Actionable Takeaway
In patients requiring ApoB lowering—especially ApoE4 carriers or those worried about cognition—use a low-to-moderate dose statin plus ezetimibe to reach ApoB targets, and monitor plasma desmosterol (and omega‑3 index where available); if desmosterol is very low or ‘brain fog’ occurs, down‑titrate the statin and rely more on ezetimibe/other non‑BBB agents while maintaining cardiovascular risk reduction.
Stay connected with Dr Onyx MD PhD for clinical insights and wellness tools that bridge science and everyday care:
Instagram ✦ X (Twitter) ✦ LinkedIn ✦ Website
From Insights to Action
Knowledge without execution changes nothing. The insights above only reach their full potential when integrated into a strategic, personalized plan. That’s where two offerings come in:
Personalized Medical AI Chatbot
Healthcare complexity is overwhelming. Clinical studies, conflicting guidelines, and fragmented records leave most patients paralyzed.
Deploy your Dr Onyx MD PhD Medical AI Chatbot—a personalized architecture that synthesizes your medical history, the latest research, and your unique condition into clear, actionable insights.
It’s not a replacement for your doctors—it’s your secret weapon for making better decisions and becoming the CEO of your own care.
👉 Deploy your Medical AI Chatbot today and take control of your health narrative
Premium Longevity Program
For people who know their most valuable asset is their health.
This year-long partnership delivers clarity, accountability, and physician-led execution. Stop collecting fragmented data and start acting on a ranked, strategic plan tailored to your biology and lifestyle.
👉 Discover the Premium Longevity Program and secure your health as your ultimate investment.